Ascendis Pharma A/S (ASND) 20-F 2 Mar 22 2021 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2021shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	ASND
Entity Registrant Name	Ascendis Pharma A/S
Entity Central Index Key	0001612042
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	56,937,682
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Document Accounting Standard	International Financial Reporting Standards
Entity Incorporation, State or Country Code	G7
Entity Address, Country	DK
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Title of 12(b) Security	Ordinary shares
Security Exchange Name	NASDAQ
Entity Address, Address Line One	Tuborg Boulevard 12
Entity Address, City or Town	Hellerup
Entity File Number	001-36815
ICFR Auditor Attestation Flag	true
Auditor Name	Deloitte Statsautoriseret Revisionspartnerselskab
Auditor Firm ID	1294
Auditor Location	Copenhagen, Denmark
Entity Address, Postal Zip Code	DK-2900
Business Contact [member]
Document Information [Line Items]
Entity Address, Country	DK
Entity Address, Address Line One	Tuborg Boulevard 12
Entity Address, City or Town	Hellerup
Contact Personnel Name	Jan Møller Mikkelsen
City Area Code	+45
Local Phone Number	70 22 22 44
Entity Address, Postal Zip Code	DK-2900
American Depositary Shares [member]
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true

Consolidated Statements of Prof

Consolidated Statements of Profit or Loss and Other Comprehensive Income - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Profit or loss [abstract]
Revenue		€ 7,778	€ 6,953	€ 13,375
Cost of sales		3,523	0	0
Gross profit		4,255	6,953	13,375
Research and development costs		295,867	260,904	191,621
Selling, general and administrative expenses		160,180	76,669	48,473
Operating profit/(loss)		(451,792)	(330,620)	(226,719)
Share of profit/(loss) of associate		12,041	(9,524)	(8,113)
Finance income		59,718	1,812	17,803
Finance expenses		3,911	80,842	1,221
Profit/(loss) before tax		(383,944)	(419,174)	(218,250)
Tax on profit/(loss) for the year		367	219	234
Net profit/(loss) for the year		(383,577)	(418,955)	(218,016)
Attributable to owners of the Company		€ (383,577)	€ (418,955)	€ (218,016)
Basic and diluted earnings/(loss) per share		€ (7)	€ (8.28)	€ (4.69)
Weighted average number of shares used for calculation (basic and diluted)	[1]	54,771,763	50,616,528	46,506,862
Statement of comprehensive income [abstract]
Net profit/(loss) for the year		€ (383,577)	€ (418,955)	€ (218,016)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translating foreign operations		3,855	(42)	(37)
Other comprehensive income/(loss) for the year, net of tax		3,855	(42)	(37)
Total comprehensive income/(loss)		(379,722)	(418,997)	(218,053)
Attributable to owners of the Company		€ (379,722)	€ (418,997)	€ (218,053)
[1]	A total of 7,085,073 warrants outstanding as of December 31, 2021 (a total of 6,148,004 warrants and 5,820,211 warrants outstanding as of December 31, 2020 and 2019, respectively) can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.

Consolidated Statements of Pr_2

Consolidated Statements of Profit or Loss and Other Comprehensive Income (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrants [member]
Statement [LineItems]
Warrants outstanding	7,085,073	6,148,004	5,820,211

Consolidated Statements of Fina

Consolidated Statements of Financial Position - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	€ 5,272	€ 5,717
Property, plant and equipment	126,049	108,112
Investment in associate	38,345	9,176
Other receivables	1,808	1,375
Marketable securities	107,561	115,280
Total non-current assets	279,035	239,660
Current assets
Inventories	75,405	0
Trade receivables	2,200	387
Income tax receivables	893	0
Other receivables	20,093	6,957
Prepayments	25,231	13,994
Marketable securities	235,797	134,278
Cash and cash equivalents	446,267	584,517
Total current assets	805,886	740,133
Total assets	1,084,921	979,793
Equity
Share capital	7,646	7,217
Distributable equity	875,989	831,494
Total equity	883,635	838,711
Non-current liabilities
Lease liabilities	97,966	85,116
Contract liabilities	2,964	0
Other liabilities	0	3,162
Total non-current liabilities	100,930	88,278
Current liabilities
Lease liabilities	6,995	6,859
Contract liabilities	2,601	363
Trade payables and accrued expenses	59,417	21,897
Other liabilities	29,952	23,384
Income tax payables	198	301
Provisions	1,193	0
Total current liabilities	100,356	52,804
Total liabilities	201,286	141,082
Total equity and liabilities	€ 1,084,921	€ 979,793

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - EUR (€) € in Thousands	Total	Issued Capital [member]	Share Premium [member]	Treasury shares [member]	Foreign Currency Translation Reserve [member]	Share-based Payment Reserve [member]	Accumulated Deficit [member]
Equity at Dec. 31, 2018	€ 280,050	€ 5,659	€ 625,250	€ 0	€ 3	€ 42,445	€ (393,307)
Statement [LineItems]
Loss for the year	(218,016)					0	(218,016)
Other comprehensive income/(loss), net of tax	(37)				(37)
Total comprehensive income/(loss)	(218,053)			0	(37)	0	(218,016)
Share-based payment (Note 7)	37,486				0	37,486	0
Capital increase	529,332	784	528,548				0
Cost of capital increase	(31,701)		(31,701)				0
Equity at Dec. 31, 2019	597,114	6,443	1,122,097	0	(34)	79,931	(611,323)
Statement [LineItems]
Loss for the year	(418,955)					0	(418,955)
Other comprehensive income/(loss), net of tax	(42)			0	(42)		0
Total comprehensive income/(loss)	(418,997)			0	(42)	0	(418,955)
Share-based payment (Note 7)	53,170				0	53,170	0
Capital increase	638,797	774	638,023				0
Cost of capital increase	(31,373)		(31,373)				0
Equity at Dec. 31, 2020	838,711	7,217	1,728,747	0	(76)	133,101	(1,030,278)
Statement [LineItems]
Loss for the year	(383,577)					0	(383,577)
Other comprehensive income/(loss), net of tax	3,855			0	3,855		0
Total comprehensive income/(loss)	(379,722)			0	3,855	0	(383,577)
Share-based payment (Note 7)	66,830				0	66,830	0
Acquisition of treasury shares	(21,605)			(21,605)
Capital increase	399,395	429	398,966				0
Cost of capital increase	(19,974)		(19,974)				0
Equity at Dec. 31, 2021	€ 883,635	€ 7,646	€ 2,107,739	€ (21,605)	€ 3,779	€ 199,931	€ (1,413,855)

Consolidated Cash Flow Statemen

Consolidated Cash Flow Statements - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net profit/(loss) for the year	€ (383,577)	€ (418,955)	€ (218,016)
Reversal of finance income	(59,718)	(1,812)	(17,803)
Reversal of finance expenses	3,911	80,842	1,221
Reversal of tax charge	(367)	(219)	(234)
Increase/(decrease) in provisions	1,193
Adjustments for non-cash items:
Non-cash consideration regarding revenue	(2,365)	(3,499)	(6,522)
Share of profit/(loss) of associate	(12,041)	9,524	8,113
Share-based payment	66,830	53,170	37,486
Depreciation	14,946	9,448	6,689
Amortization	445
Changes in working capital:
Inventories	(75,405)
Receivables	(6,659)	(1,996)	(2,182)
Prepayments	(11,238)	(6,357)	4,766
Contract liabilities (deferred income)	5,202	(495)	(6,044)
Trade payables, accrued expenses and other payables	39,186	7,884	7,530
Cash flows generated from/(used in) operations	(419,657)	(272,465)	(184,996)
Finance income received	3,697	1,326	10,056
Finance expenses paid	(1,841)	(1,504)	(717)
Income taxes received/(paid)	152	1,095	(279)
Cash flows from/(used in) operating activities	(417,649)	(271,548)	(175,936)
Investing activities
Investment in associate	(10,187)
Acquisition of property, plant and equipment	(23,704)	(19,860)	(5,159)
Reimbursement from acquisition of property, plant and equipment		5,054
Development expenditures (software)	(530)	(1,692)
Purchase of marketable securities	(226,038)	(537,752)
Settlement of marketable securities	149,880	263,051
Cash flows from/(used in) investing activities	(110,579)	(291,199)	(5,159)
Financing activities
Payment of principal portion of lease liabilities	(6,429)	(4,774)	(4,038)
Proceeds from exercise of warrants	11,537	26,882	17,377
Net proceeds from follow-on public offerings	367,884	580,542	480,254
Acquisitions of treasury shares, net of transaction costs	(21,605)
Cash flows from/(used in) financing activities	351,387	602,650	493,593
Increase/(decrease) in cash and cash equivalents	(176,841)	39,903	312,498
Cash and cash equivalents at January 1	584,517	598,106	277,862
Effect of exchange rate changes on balances held in foreign currencies	38,591	(53,492)	7,746
Bank deposits	441,736	581,872	598,106
Short-term marketable securities	4,531	2,645
Cash and cash equivalents at December 31	€ 446,267	€ 584,517	€ 598,106

General Information

General Information	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
General Information	Note 1—General Information Ascendis Pharma A/S, together with its subsidiaries, is applying its innovative TransCon technologies to build a leading, fully integrated, global biopharmaceutical company. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the “Company,” “we,” “us,” and “our”, refer to Ascendis Pharma A/S and its subsidiaries. The address of the Company’s registered office is Tuborg Boulevard 12, DK-2900 On February 2, 2015, the Company completed an initial public offering (“IPO”), which resulted in the listing of American Depositary Shares (“ADSs”), representing the Company’s ordinary shares, under the symbol “ASND” in the United States on The Nasdaq Global Select Market. The Company’s Board of Directors approved these consolidated financial statements on March 2, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Significant Accounting Policies	Note 2—Summary of Significant Accounting Policies Basis of Preparation The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”), and as adopted by the European Union (“EU”). The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3 “Significant Accounting Judgements and Estimates”. These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition. Changes in Accounting Policies and Disclosures Several amendments to and interpretations of IFRS applied for the first time in 2021, which has not had an impact on the accounting policies applied by the Company. Thus, the accounting policies applied when preparing these consolidated financial statements have been applied consistently to all the periods presented. Going Concern The Company’s Board of Directors has, at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements. Basis of Consolidation The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 19 “Investment in Group Enterprises”. Consolidation Principles Subsidiaries, which are enterprises the Company control at the reporting date, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases. Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively: • The contractual arrangement(s) with the other vote holders of the enterprise; • The Company’s voting rights and potential voting rights; and • Rights arising from other contractual arrangements. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation. Subsidiaries apply accounting policies in line with the Company’s accounting policies. When necessary, adjustments are made to bring the entities’ accounting policies in line with those of the Company. Investment in Associates An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company’s associate is accounted for using the equity method. Under the equity method, the associate is initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company’s share of net assets of the associate since the acquisition or establishment date. The consolidated statements of profit or loss include the Company’s share of result after tax of the associate after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associate and the Company are eliminated proportionally according to the Company’s interest in the associate. Unrealized gains and losses resulting from transactions between the Company and its associate is eliminated to the extent of the Company’s interest in the associate. On each reporting date, the Company determines whether there is objective evidence that the associate is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss. Foreign Currency Functional and Presentation Currency Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (“EUR”), which is also the functional currency of the parent company. Translation of Transactions and Balances On initial recognition, transactions in currencies other than the individual entity’s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary Currency Translation of Group Enterprises When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities’ balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary’s equity are recognized in other comprehensive income. Business Combinations Newly acquired or newly established subsidiaries are recognized in the consolidated financial statements from the time of acquiring or establishing such enterprises. Time of acquisition is the date on which the Company obtains control over the enterprise. When acquiring new enterprises over which the Company obtains control, the acquisition method is applied. Under this method, assets, liabilities and contingent liabilities of these enterprises are identified and measured at fair value as of the acquisition date. Restructuring costs are only recognized in the pre-acquisition The acquisition price for an enterprise consists of the fair value of the consideration paid for the acquired enterprise. Costs that are attributable to the acquisition of the enterprise are recognized in the consolidated statement of profit or loss when incurred. The excess of the consideration transferred, the amount of any non-controlling Goodwill is subject to an annual impairment test. Impairment is calculated as the difference between the recoverable amount of the cash-generating unit that the goodwill relates to, and its carrying amount. Any impairment loss is recognized in the consolidated statement of profit or loss in a separate line item. Revenue Revenue from Commercial Sale of Products Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions including prompt pay discounts, shelf stock adjustments and applicable sales rebates attributed to various commercial arrangements, managed healthcare organizations, and government programs such as Medicaid and the 340B Drug Pricing Program (chargebacks), and co-pay “sale-or-return” Unsettled sales rebates and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and rebates that are payable to customers are off-set Other Revenue Other revenue is primarily generated from collaboration and license agreements. In addition, other revenue is generated from feasibility studies for potential partners to evaluate if TransCon technologies enable certain advantages for their product candidates of interest. Such feasibility studies are often structured as short-term agreements with fixed fees for the work that the Company performs. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met: • the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and • the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). Under collaboration, license, and other agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified. The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. In the transaction price, variable consideration, including milestone payments, is only included to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services are transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. Other revenue is stated net of value added taxes, and discounts. Research and Development Costs Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (“CROs”) and Contract Manufacturing Organizations (“CMOs”), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company’s intellectual property portfolio, and depreciation of non-current Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human Development activities relate to activities following an IND, or equivalent, and typically involves a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administrated in a small group of humans), and further into Phase II and III, which include administration of drugs in large patient groups. Following, and depending on clinical trial results, a Biologic License Application (“BLA”) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the drug products. Long-term extension trials may be ongoing following submission of a BLA. Development costs also include manufacturing costs related to validation batches, or process performance qualification batches on development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred. Selling, General and Administrative Expenses Selling, general and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current Share-based Incentive Programs Share-based incentive programs comprise warrant programs and Restricted Stock Unit programs (“RSU-programs”) The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes valuation model. For RSU-programs, The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest. Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately. Where the terms and conditions for an equity-settled grant is modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that was specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7 “Share-based Payment”. Finance Income and Expenses Finance income and expenses comprise interest income and expenses and realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies. Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability. Income Taxes Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year’s taxable income, adjusted for prepaid tax. When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible. Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future. Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized. Intangible assets Goodwill Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represent the lowest level within the Company at which the goodwill is monitored for internal management purposes. Software Software assets comprise administrative applications and serve general purposes to support the Company’s operations. Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained. Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use. Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. During the period of development, the asset is tested for impairment, at least annually, or if there are indications that the asset is impaired. Expenditures, that do not meet the criteria above are recognized as an expense as incurred. Property, Plant and Equipment Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and the costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred. Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred. If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset’s cost, respectively. The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended. Depreciation is calculated on a straight-line basis, based on an asset’s expected useful life, being within the following ranges: Process plant and machinery 5 - 10 years Other equipment 3 - 5 years Leasehold improvements 3 - 11 years Right-of-use 2 - 11 years Depreciation methods, useful lives and residual amounts are reassessed at least annually. Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the “Impairment” section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general and administrative expenses, as appropriate. Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either other operating income or other operating expenses, as appropriate. Impairment The recoverable amount of goodwill and development projects in progress (software assets) is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-financial Inventories Inventories comprise raw materials, work in progress and finished goods. Work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity. Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production. If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales when incurred. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs. Manufacturing of pre-launch pre-launch pre-launch pre-launch Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized. Receivables Receivables comprise trade receivables, income tax receivables and other receivables. Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments. Prepayments Prepayments comprise advance payments relating to a future financial period. Prepayments are measured at cost. Marketable Securities Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets. At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding. This assessment is referred to as the SPPI-test. All marketable securities held at the reporting date have passed the SPPI-test. Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired. Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current Cash and Cash Equivalents Cash and cash equivalents comprise cash and on-demand Allowance for Expected Credit Losses on Financial Assets Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (“ECL”) Model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate. For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment. For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default. Shareholders’ Equity The share capital comprises the nominal amount of the parent company’s ordinary shares, each at a nominal value of DKK 1, or approximately €0.13. All shares are fully paid. Share premium comprises the amounts received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the parent company’s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company’s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits. Treasury shares reserve comprise own equity instrument which are recognized at cost and included within equity. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company’s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company’s shareholders. Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency. The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company’s shareholders. Share-based payment reserve represents the corresponding entries to the share-based payment recognized in the consolidated statement of profit or loss, arising from warrant programs and restricted stock units programs. The share-based payments reserve is an unrestricted reserve that is available to be distributed as dividends to the Company’s shareholders. Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company’s operations. A positive reserve is available to be distributed as dividends

Significant Accounting Judgemen

Significant Accounting Judgements and Estimates	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Significant Accounting Judgements and Estimates	Note 3 – Significant Accounting Judgements and Estimates In the application of the Company’s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes, that require a material adjustment to assets and liabilities in future periods. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management’s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the years presented in the consolidated financial statements. Significant Accounting Judgements Critical accounting judgements which have a material impact on the consolidated financial statements are described in the following sections. Other Revenue Other revenue is primarily generated from collaboration and license agreements, which typically involve multiple promises, and thus require significant judgements by management on certain areas including: • Determining whether the promises in the agreements are distinct performance obligations; • Identifying and constraining variable consideration in the transaction price including milestone payments; • Allocating transaction price to identified performance obligations based on their relative stand-alone selling prices; and • Determining whether performance obligations are satisfied over time, or at a point in time. Three license agreements with the Company’s associate VISEN Pharmaceuticals (“licensee”), grant the licensee exclusive rights to develop, manufacture, and commercialize patented product candidates in Greater China, including the right to grant sub-licenses Critical judgements relating to the license agreements are described below. Classification of License Agreements Collaboration and license agreements within the Company’s industry are often structured so that each party contributes its respective skills in the various phases of a development project, and significant judgement is required by management to determine whether such agreements comprise customer/supplier relationship or joint arrangements where parties share risks and rewards. It has been concluded that no joint control exists for the Company’s license agreements and the parties do not have any financial obligations on behalf of each other. Accordingly, since neither of the license agreements are considered to be joint arrangements, these are classified as contracts with customers. Identifying Performance Obligations In determination of the performance obligations and allocation of the transaction price, the stand-alone values of the promises and the Company’s responsibility in the development activities have been considered. Since licensed product candidates are all in phase 1 clinical trials or later stages of development, the licensee can benefit from each promise in the contract either on their own or together with readily available resources. Accordingly, licenses, development services, and clinical trial supplies are all considered distinct performance obligations. Classification of Licenses as “Right-to-Use” “Right-to-Access” Management has considered whether the Company is obligated or expected to perform research and development activities that significantly affect the licensee’s ability to benefit from the product candidates. Since licensed products are patented drug formulas, future activities performed by the Company do not affect their stand-alone functionalities. Accordingly, all three licenses have been classified as “right-to-use”, Internally Generated Intangible Assets Development of Drug Candidates IAS 38, “Intangible Assets” prescribes that intangible assets arising from development projects must be recognized in the consolidated statements of financial position if the criteria for capitalization are met. That means (1) that the development project is clearly defined and identifiable; (2) that technological feasibility, adequate resources to complete and a market for the product or an internal use of the project can be documented; (3) that the expenditure attributable to the development project can be measured reliably; and (4) that the Company has the intent to produce and market the product. Such an intangible asset shall be recognized if it can be demonstrated that the future income from the development project will exceed the aggregate cost of development, production, sale and administration of the product. Due to the risk associated with drug development, future income from development projects related to drug candidates cannot be determined with sufficient certainty until the development activities have been completed and the necessary marketing approvals have been obtained. Accordingly, the Company does not recognize internally generated intangible assets at this time. Leases Determination of Lease Term Certain lease arrangements include contractual rights (not obligations) to either extend the lease after the initial term, or not to terminate the lease within the enforceable lease term, i.e., periods where lessor cannot terminate the lease. Those options cover periods in the range from two non-cancellable Significant Estimation Uncertainties The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. Revenue and Provisions Provision for Sales Rebates and Product Returns Sales rebates and product returns are considered variable consideration and constrained to the extent that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties associated with the rebate item is subsequently resolved, or for product returns, when the sold products are distributed to patients. Provisions for unsettled sales rebates and product returns are estimated on the basis of a percentage of sales as defined by individual agreements and contracts, and for government rebates by individual state- and plan agreements. Further input in the calculations is based on payer channel mix, current contract prices under eligible programs, patient groups and current inventory levels in the distribution channels. Provisions are adjusted to absolute amounts and recognized as other liabilities when estimated sales rebates and returns are processed. Share-Based Payment Warrant Compensation Costs IFRS 2, “Share-Based Payment” requires an entity to reflect in its consolidated statement of profit or loss and financial position, the effects of share-based payment transactions. Warrant compensation costs are recognized as cost of sales, research and development costs or selling, general and administrative expenses, as appropriate, over the vesting period, based on management’s best estimate of the number of warrants that will ultimately vests, which is subject to uncertainty. Warrant compensation costs are measured according to the grant date fair values of the warrants granted. Estimating fair values requires the Company to apply generally accepted valuation models and apply these models consistently according to the terms and conditions of the specific warrant program. Under all warrant programs, the Black-Scholes option-pricing model has been applied to determine the fair value of warrants granted. Subjective judgements and assumptions, which are subject to estimation uncertainties, need to be exercised in determining the appropriate input to the valuation model. These inputs include expected volatility of the Company’s share price for a historic period equaling the expected lifetime of the warrants, reflecting the assumption that the historical volatility over a period similar to the life of the warrants is indicative of future trends. In 2021, the Company has for the first time, in connection with determining the grant date fair value of warrants and accordingly, warrant compensation costs, applied the price of the Company’s ADSs, each representing one ordinary share of the Company, as input for expected volatility. Until December 31, 2020, the expected volatility was calculated using a simple average of daily historical data of comparable publicly traded companies, as the Company did not have sufficient data for the volatility of the Company’s own share price. Refer to Note 7 “Share-based Payment”, for additional details on the Company’s warrant program and option-pricing model input. Warrant compensation cost recognized in the consolidated statement of profit or loss was €66.1 million, €53.2 million and €37.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. Prepayments and Accruals Project Development Costs Development of drug candidates requires significant resources, and establishment of long-term working relationships with CROs and CMOs. Work performed by CROs and CMOs and other suppliers, often comprise deliveries for more than one reporting period, and where payment terms for contractual work do not necessarily reflect the stage of completion of the individual projects and activities. Accordingly, determination of the stage of completion for ongoing project activities include estimation uncertainties as future efforts to complete the specific activity may be difficult to predict. On each reporting date, all significant ongoing activities are reviewed to determine the stage of completion and compared to the invoices received. Accruals are recognized for individual projects where the stage of completion exceeds costs of invoices received. Similarly, prepayments are recognized for invoiced costs in excess of the stage of completion. The Company has implemented accrual calculation models and policies, to ensure that consistent accrual procedures are applied, which includes analyzing significant project stages and payment structures, comparing project milestones to planned performance, and revisiting prior periods estimates. As of December 31, 2021, the consolidated statement of financial position included prepaid project costs of €8.0 million and accrued project costs of €23.5 million, compared to €10.5 million and €17.0 million, respectively, as of December 31, 2020.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Revenue	Note 4—Revenue Revenue from commercial sale of products relates to sale of SKYTROFA ® In addition, other revenue is generated primarily from three license agreements, which were entered into in 2018. The licenses grant VISEN Pharmaceuticals (“VISEN”), exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China. As consideration, the Company has received up-front, non-refundable, non-cash Revenue has been recognized in the consolidated statements of profit or loss with the following amounts: 2021 2020 2019 (EUR’000) Revenue from external customers Commercial sale of products 943 — — Rendering of services 751 2,140 9,919 Sale of clinical supply 3,719 2,206 804 “Right-to-use” 2,365 2,607 2,652 Total revenue 7,778 6,953 13,375 Attributable to Commercial customers 943 — — Collaboration partners and license agreements (1) 6,835 6,953 13,375 Total revenue 7,778 6,953 13,375 Specified by timing of recognition Recognized over time 751 2,140 9,919 Recognized at a point in time 7,027 4,813 3,456 Total revenue 7,778 6,953 13,375 Specified per geographical location North America 6,856 2,679 2,652 China 922 4,274 10,723 Total revenue 7,778 6,953 13,375 (1) Revenue from collaboration partners and license agreements includes recognition of previously deferred revenue/internal profit from associate of €2.4 million, €3.5 million and €6.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. Revenue from one collaboration partner amounted to 95 % of total revenue from collaboration partners and license agreements.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Segment Information	Note 5—Segment Information The Company is managed and operated as one business unit. No separate business areas or separate business units have been identified in relation to product candidates or geographical markets. Accordingly, except for entity wide disclosures, no information on business segments or geographical markets is disclosed. Entity wide disclosures regarding revenue are included in Note 4 “Revenue”. The Company’s intangible assets and property, plant and equipment located by country are specified below, and defines the Company’s non-current 2021 2020 (EUR’000) Non-current Denmark (domicile country) 29,656 20,288 North America 91,755 85,476 Germany 9,910 8,065 Total non-current 131,321 113,829 Investment in associate 38,345 9,176 Marketable securities 107,561 115,280 Other receivables 1,808 1,375 Total non-current 279,035 239,660

Employee costs

Employee costs	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Employee costs	Note 6—Employee costs 2021 2020 2019 (EUR’000) Employee costs Wages and salaries 104,583 77,374 49,142 Share-based payment 66,830 53,170 37,486 Pensions (defined contribution plans) 2,416 943 648 Social security costs 4,571 5,358 3,613 Total employee costs 178,400 136,845 90,889 Included in the profit or loss — — — Cost of sales 1,380 — — Research and development costs 106,558 92,468 61,890 Selling, general and administrative expenses 70,462 44,377 28,999 Total employee costs 178,400 136,845 90,889 Average number of employees 573 410 274 Key Management Personnel comprises the Board of Directors, the Executive Board and Non-executive Compensation to Key Management Personnel included within total employee costs is summarized below: Board of Directors (1) Executive Board (2) Non-executive 2021 2020 2019 2021 2020 2019 2021 2020 2019 (EUR ‘000) Compensation Wages and salaries 296 250 265 2,699 2,372 1,815 5,547 5,272 4,706 Share-based payment 2,032 1,913 1,864 8,770 6,359 5,303 14,906 13,912 11,123 Pensions (defined contribution plans) — — — 23 — — 120 89 54 Social security costs — — — 49 100 94 60 122 84 Total compensation 2,328 2,163 2,129 11,541 8,831 7,212 20,633 19,395 15,967 (1) The Board of Directors comprised six to seven persons in 2021. At December 31, 2021, the Board of Directors comprised six persons. For 2020 and 2019, the Board of Directors comprised seven persons. (2) The Executive Board comprised two to four persons in 2021. At December 31, 2021, the Executive Board comprised four persons. For 2020 and 2019, the Executive Board comprised two persons.

Share-based Payment

Share-based Payment	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Share-based Payment	Note 7—Share-based Payment As an incentive to employees, members of the Board of Directors and select consultants, Ascendis Pharma A/S has established warrant programs and, since December 2021, Restricted Stock Unit programs (“RSU programs”), which are equity-settled share-based payment transactions. Restricted Stock Unit Program Restricted Stock Units (“RSUs”) are granted by the Board of Directors in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to the Executive Board, select employees and members of the Board of Directors (“RSU-holders”) RSU-holder Vesting Conditions RSUs granted vest over a predetermined service period, and accordingly require RSU-holders to be employed, or provide a specified period of service. RSUs vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and in the case of RSUs granted to the Company’s Chief Executive Officer, subject to the achievement of performance conditions as determined by the Company’s Board of Directors. RSUs generally cease to vest from the date of termination of employment, or for Board of Directors, termination of board membership, whereas unvested RSUs will lapse. In addition, vesting may be contingent upon additional vesting criteria (non-market No later than 30 days after each vesting date, the Company transfers the applicable number of ADSs corresponding to the vested RSUs to the RSU-holders. RSU-holder, Adjustments RSU-holders RSU Activity RSUs were granted for the first time in December 2021. The following table specifies the number of RSUs granted, their fair value at grant date, and outstanding RSUs at December 31, 2021: Total Outstanding at January 1, 2021 — — Granted, December 2021 148,148 123.46 Outstanding at December 31, 2021 148,148 123.46 Vested at the reporting date — — Warrant program Warrants are granted by the Board of Directors in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board of Directors and select consultants (“warrantholders”). Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK 1. The exercise price is fixed at the fair market value of the Company’s ordinary shares at the time of grant as determined by the Board of Directors. Vested warrants may be exercised in two or four annual exercise periods as described below. Apart from exercise prices, exercise periods and vesting conditions for board members, the programs are similar. Vesting Conditions Warrants granted vest over a predetermined service period, and accordingly require warrantholders to be employed, or provide a specified period of service. Warrants generally cease to vest from the date of termination in the event that (i) the employee terminates the employment contract and the termination is not a result of breach of the employment terms by the Company, or (ii) in the event that the Company terminates the employment contract and the employee has given the Company good reason to do so. In relation to board members, the vesting shall cease on the termination date of the board membership regardless of the reason. In relation to consultants, the vesting shall cease on the termination date of the consultancy relationship. The warrantholder will, however, be entitled to exercise vested warrants in the first exercise period after termination. In the event that the employment contract is terminated, and the employee has not given the Company good reason to do so, the warrantholder may keep the right to continued vesting and exercise of warrants as if the employment was still in effect. In such case, any expense not yet recognized for the outstanding warrants is recognized immediately. Warrants granted 2012 until November 2021 Warrants granted from 2012 until November 2021, generally vest over 48 months with 1/48 of the warrants vesting per month from the date of grant. However, effective from January 2015, certain warrants granted to board members vest over 24 months with 1/24 of the warrants vesting per month from the date of grant. Warrants granted from December 2021 For warrants granted to employees and consultants, 25% of the warrants vest one year after the date of grant, and the remaining 75% of the warrants granted vest over 36 months, with 1/36 of the warrants vesting per month, from one year after the date of grant. For warrants granted to board members upon the board members accession, 25% of the warrants granted vest one year after the date of grant, and the remaining 75% of the warrants granted shall vest over 36 months, with 1/36 per month from one year after the date of grant. Regarding subsequent grants of warrants to board members, 50 % of the warrants vest one year after the date of grant, and the remaining 50% of the warrants vest over 12 months, with 1/12 per month from one year after the date of grant. Exercise Periods Vested warrants may be exercised during certain exercise periods each year, within certain periods after publication of earnings data of a fiscal quarter, interim and annual reports. For outstanding warrants granted in the period 2012 to 2014, there are two annual exercise periods. For outstanding warrants granted in November 2014 in connection with the Preference D financing, there are four annual exercise periods. For these outstanding warrants, the last exercise period is 21 days from and including the day after the publication of the interim report for the first half of 2023. For outstanding warrants granted in December 2015 and later, there are four annual exercise periods. Warrants expire ten years after the grant date. Warrants not exercised by the warrantholder during the last exercise period shall become null and void without further notice or compensation or payment of any kind to the warrantholder. If the warrantholder is a consultant, advisor or board member, the exercise of warrants is conditional upon the warrantholder’s continued service to the Company at the time the warrants are exercised. If the consultant’s, advisor’s or board member’s relationship with the Company should cease without this being attributable to the warrantholder’s actions or omissions, the warrantholder shall be entitled to exercise vested warrants in the pre-defined exercise periods. Adjustments Warrantholders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain corporate changes. Events giving rise to an adjustment include, among other things, increases or decreases to the share capital at a price below or above market value, the issuance of bonus shares, changes in the nominal value of each share, and payment of dividends in excess of 10% of the Company’s equity. Warrant Activity The following table specifies the number and weighted average exercise prices of, and movements, in warrants during the year: Total Weighted Outstanding at January 1, 2019 5,611,629 29.03 Granted during the year 1,300,600 97.01 Exercised during the year (1) (1,058,722 ) 16.33 Forfeited during the year (33,296 ) 58.49 Expired during the year — — Outstanding at December 31, 2019 5,820,211 46.36 Vested at the reporting date 2,705,693 24.93 Granted during the year 1,485,931 137.57 Exercised during the year (1) (905,395 ) 30.56 Forfeited during the year (252,743 ) 64.99 Expired during the year — — Outstanding at December 31, 2020 6,148,004 69.97 Vested at the reporting date 3,044,827 37.29 Granted during the year 1,445,981 122.03 Exercised during the year (1) (312,296 ) 38.43 Forfeited during the year (196,616 ) 119.58 Expired during the year — — Outstanding at December 31, 2021 7,085,073 80.30 Vested at the reporting date 4,022,011 52.63 (1) The weighted average share price (listed in $) at the date of exercise was €124.62, €128.32 and €108.54 for the years ended December 31, 2021, 2020 and 2019, respectively. As of December 31, 2021, the Board of Directors was authorized to grant up to 1,316,588 additional warrants to employees, board members and select consultants without preemptive subscription rights for the shareholders of Ascendis Pharma A/S. The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at December 31, 2021 per grant year. Number of Weighted Weighted Granted in 2012-2017 2,059,718 20.96 53 Granted in 2018 1,209,072 54.52 82 Granted in 2019 1,071,441 97.23 93 Granted in 2020 1,310,094 137.89 104 Granted in 2021 1,434,748 122.03 118 Outstanding at December 31, 2021 7,085,073 80.30 87 At December 31, 2021, the exercise prices of outstanding warrants under the Company’s warrant programs range from €6.48 to €145.50 depending on the grant dates. The range of exercise prices for outstanding warrants was €6.48 to €145.50 and €6.48 to €107.14 for the years ended December 31, 2020 and 2019, respectively. The weighted average remaining life for outstanding warrants was 91 months and 94 months, for the financial years ended December 31, 2020 and 2019, respectively. Warrant Compensation Costs Warrant compensation costs are recognized in the consolidated statement of profit or loss over the vesting period of the warrants granted. Warrant compensation costs are determined with basis in the grant date fair value of the warrants granted and recognized over the vesting period. Fair value of the warrants is calculated at the grant dates by use of the Black-Scholes Option Pricing model with the following assumptions: (1) an exercise price equal to the estimated market price of the Company’s shares at the date of grant; (2) an expected lifetime of the warrants determined as a weighted average of the time from grant date to date of becoming exercisable and from grant date to expiry of the warrants; (3) a risk-free interest rate equaling the effective interest rate on a Danish government bond with the same lifetime as the warrants; (4) no payment of dividends; and (5) an expected volatility using the Company’s own share price (from 2021). The following table summarizes the input to the Black-Scholes Option Pricing model and the calculated fair values for warrant grants in 2021, 2020 and 2019: 2021 2020 2019 Expected volatility 48 – 49% 52 – 55% 52 – 54% Risk-free interest rate (0.54)–(0.27)% (0.93)–(0.32)% (0.77)–(0.05)% Expected life of warrants (years) 6.0 5.05 – 7.10 5.05 – 7.10 Weighted average exercise price € 122.03 € 137.57 € 97.01 Fair value of warrants granted in the year € 45.91 – 64.28 € 48.43 – 75.77 € 27.24 – 55.64

Principal Accountant Fees and S

Principal Accountant Fees and Services	12 Months Ended
	Dec. 31, 2021
Auditor's remuneration [abstract]
Principal Accountant Fees and Services	Note 8— Principal Accountant Fees and Services The following table sets forth, for each of the years indicated, the fees billed by the Company’s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants. 2021 2020 2019 (EUR’000) Principal accountant fees and services Audit fees 771 599 700 Tax fees 87 104 7 All other fees 13 22 — Total principal accountant fees and services 871 725 707

Tax on Profit_(Loss) for the Ye

Tax on Profit/(Loss) for the Year and Deferred Tax	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Tax on Profit/(Loss) for the Year and Deferred Tax	Note 9—Tax on Profit/(Loss) for the Year and Deferred Tax 2021 2020 2019 (EUR’000) Tax on profit/(loss) for the year: Current tax (expense)/income 367 219 234 367 219 234 2021 2020 2019 (EUR’000) Tax for the year can be explained as follows: Profit/(loss) before tax (383,944 ) (419,174 ) (218,250 ) Tax at the Danish corporation tax rate of 22% 84,468 92,218 48,015 Tax effect of: Non-deductible (14,800 ) (11,815 ) (8,249 ) Additional tax deductions 17,117 24,564 10,875 Impact from associate 3,169 (1,326 ) (1,680 ) Other effects including effect of different tax rates 305 2,673 1,602 Deferred tax asset, not recognized (89,892 ) (106,095 ) (50,329 ) Tax on profit/(loss) for the year 367 219 234 Effective tax rate (0.10)% (0.05)% (0.11)% 2021 2020 2019 (EUR’000) Specification of Deferred Tax Assets Tax deductible losses 313,011 227,234 123,234 Other temporary differences 12,856 7,726 5,631 Deferred tax asset, not recognized (325,867 ) (234,960 ) (128,865 ) Total Deferred Tax Assets at December 31 0 0 0 No changes to deferred tax have been recognized in the consolidated statement of profit or loss for 2021, 2020 or 2019. Deferred tax assets have not been recognized in the consolidated statements of financial position due to uncertainty relating to future utilization. Deferred tax assets can be carried forward without timing limitations. The Company had tax losses carried forward of €1,437.0 million and €1,043.8 million at December 31, 2021 and 2020, respectively. Tax losses can be carried forward infinitely, where certain limitations exist for amounts to be utilized each year. Under Danish tax legislation, tax losses may be partly refunded by the tax authorities to the extent such tax losses arise from research and development activities. For the year ended December 31, 2021, the jointly taxed Danish entities had a negative taxable income, and accordingly were entitled to a tax refund of approximately €0.7 million for each of the years ended December 31, 2021, 2020 and 2019, respectively. The Company is entitled to additional tax deductions, determined by annual warrants exercised by employees. For the year ended December 31, 2021, the Company was entitled to additional tax deductions with a tax value of The parent company Ascendis Pharma A/S is jointly taxed with its Danish subsidiaries. The current Danish corporation tax is allocated between the jointly taxed Danish companies in proportion to their taxable income (full absorption with refunds for tax losses). These companies are taxed under the on-account

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Intangible Assets	Note 10—Intangible Assets Goodwill Software Total (EUR’000) Cost: At January 1, 2020 3,495 — 3,495 Additions — 2,222 2,222 Disposals — — — Foreign exchange translation — — — At December 31, 2020 3,495 2,222 5,717 Additions — — — Disposals — — — Foreign exchange translation — — — At December 31, 2021 3,495 2,222 5,717 Accumulated amortization and impairments: At January 1, 2020 — — — Amortization charge — — — Impairment charge — — — Disposals — — — Foreign exchange translation — — — At December 31, 2020 — — — Amortization charge — (445 ) (445 ) Impairment charge — — — Disposals — — — Foreign exchange translation — — — At December 31, 2021 — (445 ) (445 ) Carrying amount: At December 31, 2020 3,495 2,222 5,717 At December 31, 2021 3,495 1,777 5,272 At the reporting date, no internally generated intangible assets from development of pharmaceutical drug candidates have been recognized. Thus, all related research and development costs incurred for the years ended December 31, 2021, 2020, and 2019, were recognized in the consolidated statements of profit or loss. Goodwill relates to the acquisition of Complex Biosystems GmbH (now Ascendis Pharma GmbH) in 2007. Goodwill was calculated as the excess amount of the purchase price to the fair value of identifiable assets acquired, and liabilities assumed at the acquisition date. Ascendis Pharma GmbH was initially a separate technology platform company but is now an integral part of the Company’s research and development activities. Accordingly, it is not possible to look separately at Ascendis Pharma GmbH when considering the recoverable amount of the goodwill. Goodwill is monitored and tested for impairment on a consolidated level as the Company is considered to represent one cash-generating unit. Goodwill is tested for impairment on an annual basis at December 31, or more frequently, if indications of impairment are identified. There have been no impairments recognized in any of the periods presented. The recoverable amount of the cash-generating unit is determined based on an estimation of the Company’s fair value less costs of disposal. The fair value of goodwill has been determined after taking into account the market value of the Company’s ADSs as of the reporting date. The computation of the market value including an estimation of selling costs, significantly exceeded the carrying amount of the net assets, leaving sufficient value to cover the carrying amount of goodwill. Considering the excess value, no further assumptions are deemed relevant to be applied in determining whether goodwill is impaired. Amortization charges are recognized through general and administrative expenses.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Property, Plant and Equipment	Note 11—Property, Plant and Equipment Plant and Other Leasehold Right-of-Use Total (EUR’000) Cost: At January 1, 2020 8,038 3,944 4,288 40,119 56,389 Additions 7,169 1,635 4,849 64,582 78,235 Disposals (296 ) (221 ) (14 ) (531 ) Foreign exchange translation (289 ) (183 ) (588 ) (5,135 ) (6,195 ) At December 31, 2020 14,622 5,175 8,535 99,566 127,898 Additions 2,810 3,386 8,780 10,812 25,788 Disposals (772 ) (10 ) — (1,040 ) (1,822 ) Foreign exchange translation 286 271 752 6,797 8,106 At December 31, 2021 16,946 8,822 18,067 116,135 159,970 Accumulated depreciation: At January 1, 2020 (3,971 ) (1,563 ) (558 ) (5,228 ) (11,320 ) Depreciation charge (1,030 ) (956 ) (605 ) (6,857 ) (9,448 ) Disposals 204 191 7 — 402 Foreign exchange translation 16 41 22 501 580 At December 31, 2020 (4,781 ) (2,287 ) (1,134 ) (11,584 ) (19,786 ) Depreciation charge (1,499 ) (1,200 ) (1,284 ) (10,963 ) (14,946 ) Disposals 772 10 — 1,040 1,822 Foreign exchange translation (19 ) (70 ) (70 ) (852 ) (1,011 ) At December 31, 2021 (5,527 ) (3,547 (2,488 ) (22,359 ) (33,921 ) Carrying amount: At December 31, 2020 9,841 2,888 7,401 87,982 108,112 At December 31, 2021 11,419 5,275 15,579 93,776 126,049 Assets under construction amounts to €1.9 million and €2.3 million at December 21, 2021 and 2020, respectively. Of total additions, €2.1 million and €1.0 million was unpaid at December 31, 2021 and 2020, respectively. Depreciation charges are specified below: 2021 2020 2019 (EUR’000) Depreciation charges Cost of sales 252 — — Research and development costs 10,102 7,311 5,282 Selling, general and administrative expenses 4,592 2,137 1,406 Total depreciation charges

Investment in Associate

Investment in Associate	12 Months Ended
	Dec. 31, 2021
Investments accounted for using equity method [abstract]
Investment in Associate	Note 12—Investment in Associate VISEN is a private Company with business activities within development, manufacturing and commercialization of endocrinology rare disease therapies in Greater China. The Company’s interest in VISEN is accounted for as an associate using the equity method in the consolidated financial statements as the Company has determined that it has significant influence but not joint control. The Company has granted VISEN exclusive rights to develop and commercialize TransCon hGH, TransCon PTH and TransCon CNP in Greater China, and as consideration for the granting of such rights has received a 50% ownership of VISEN’s issued and outstanding shares. The other investors contributed, in aggregate, $40.0 million in cash as their consideration for remaining 50% ownership. On January 8, 2021, the Company entered into an equity investment of $12.5 million as part of VISEN’s $150 million Series B financing. Following VISEN’s Series B financing, the Company retained 43.93% of VISEN’s issued and outstanding shares. As a result, a non-cash The following table illustrates the summarized relevant financial information of VISEN: VISEN Pharmaceuticals Principal place of business China 2021 2020 (EUR’000) Statement of profit or loss Profit/(loss) for the year from continuing operations (69,283 ) (19,049 ) Total comprehensive income ( 69,306 ) (19,049 ) Statement of financial position Non-current 16,599 16,635 Current assets 130,825 20,373 Total assets 147,424 37,008 Equity 135,333 33,708 Non-current 1,545 152 Current liabilities 10,546 3,148 Total equity and liabilities 147,424 37,008 Company’s share of equity before eliminations 59,455 16,854 Elimination of internal profit and other equity method adjustments (21,110 ) (7,678 ) Company’s share of equity 38,345 9,176 Investment in associate at December 31 38,345 9,176 Present ownership at December 31 43.93% 50% Transactions and outstanding balances as of December 31 Sale of goods and services to associate 6,472 6,880 Trade receivables from associate 1,644 184 Contract liabilities 5,565 —

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventories [Abstract]
Inventories	Note 13—Inventories The Company’s inventories relate to commercial products of SKYTROFA (lonapegsomatropin-tcgd), related work in progress (intermediates) and raw materials. Marketing approval for SKYTROFA (lonapegsomatropin-tcgd) in the United States was obtained on August 25, 2021, and accordingly, all inventories until this date had been written down. Subsequent to obtaining marketing approval, a reversal of write-down on pre-launch inventories was recognized through research and development costs in the consolidated statement of profit or loss with a positive impact of €53.7 million. 2021 (EUR’000) Inventories Raw materials and consumables 2,248 Work in progress 68,865 Finished goods 4,292 Total inventories 75,405

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Text Block Abstract [Abstract]
Leases	Note 14—Leases The Company primarily leases office and laboratory facilities. Lease arrangements contain a range of different terms and conditions and are typically entered into for fixed periods. Generally, the lease terms are between two two non-cancellable To accommodate the current and future development of the Company, additional leases related to office facilities were entered into in 2021. In 2021, the Company entered into an additional facility lease in Germany with an enforceable lease term of four years. The lease commences in January 2022. At that date an initial lease liability of €2.3 million will be recognized. Refer to Note 21 “Subsequent events” for details regarding one lease entered, subsequent to the reporting date. Leases Liabilities and Payments Development in lease liabilities are specified below: Beginning Cash payments Non-cash End of Payment of Payment Additions Accretion of Foreign (EUR’000) Lease liabilities December 31, 2021 91,975 (6,429 ) (1,326 ) 10,812 3,396 6,533 104,961 December 31, 2020 36,619 (4,781 ) (1,209 ) 64,582 1,617 (4,853 ) 91,975 The maturity analysis of lease liabilities is disclosed in Note 17 Expenses Relating to Leases The following expenses relating to lease activities are recognized in the consolidated statements of profit or loss: 2021 2020 2019 (EUR’000) Lease expense Depreciation 10,963 6,857 5,237 Expenses relating to short term leases and leases of low value assets 186 470 202 Lease interest 3,396 1,617 1,014 Total lease expenses 14,545 8,944 6,453

Contract liabilities

Contract liabilities	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Contract liabilities	Note 15—Contract Liabilities At December 31, 2021, contract liabilities comprise unsatisfied performance obligations relating to delivery of clinical and commercial supply under one of the Company’s license agreements. Contract liabilities are expected to be recognized as revenue with €2.6 million in 2022, and €3.0 million in 2023-2026. Revenue recognized from contract liabilities was €0.4 million, €1.0 million and €6.1 million for the years ended December 31, 2021, 2020 and 2019, respectively, and related to feasibility studies, and research and development services under the Company’s license agreements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Commitments and Contingencies	Note 16—Commitments and Contingencies Contractual commitments for the acquisition of property, plant and equipment were €8.4 million and €15.8 million for the years ended December 31, 2021 and 2020, respectively. Further, with certain suppliers, the Company has agreed minimum commitments related to the manufacturing of product supply, subject to continuous negotiation and adjustments according to the individual contractual terms and conditions. Delivery of product supply is recognized when the Company obtains control of the goods. In addition, the Company has commitments related to short-term leases and leases of low value assets, contracts of various lengths in respect of research and development with CROs, and IT and facility related services. Costs relating to those commitments are recognized as services are received. The Company is not aware of any significant legal claims or disputes.

Financial Risk Management and F

Financial Risk Management and Financial Instruments	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Financial Risk Management and Financial Instruments	Note 17—Financial Risk Management and Financial Instruments Financial assets and financial liabilities comprise the following: 2021 2020 (EUR’000) Financial assets Trade receivables 2,200 387 Other receivables 12,276 2,251 Marketable securities 343,358 249,558 Cash and cash equivalents 446,267 584,517 Financial assets measured at amortized cost 804,101 836,713 Financial liabilities Lease liabilities 104,961 91,975 Trade payables and accrued expenses 59,417 21,897 Financial liabilities measured at amortized cost 164,378 113,872 Finance income and expenses are specified below: 2021 2020 2019 (EUR’000) Finance income Interest income 692 1,812 10,056 Exchange rate gains 59,026 — 7,747 Total finance income 59,718 1,812 17,803 Finance expenses Interest expenses 3,911 1,918 1,221 Exchange rate losses — 78,924 — Total finance expenses 3,911 80,842 1,221 Interest income and interest expenses relate to financial assets and liabilities measured at amortized cost. Exchange rate gains and Capital Management The Company manages capital to ensure that all group enterprises will be able to continue as going concerns while maximizing the return to shareholders through the optimization of debt and equity balances. The overall strategy in this regard has remained unchanged since 2012. Capital Structure The Company’s capital structure consists only of equity comprising issued capital, reserves and retained earnings/accumulated deficits. Although the Company is not subject to any externally imposed capital requirements, the capital structure is reviewed on an ongoing basis. Since the Company does not hold external debt, such review currently comprises a review of the adequacy of the Company’s capital compared to the resources required for carrying out ordinary activities. Development in the Company’s share capital and treasury shares reserves are described in the following sections. Other equity reserves are described in Note 2 “Summary of Significant Accounting Policies”. Share Capital The share capital of Ascendis Pharma A/S consists of 56,937,682 fully paid shares at a nominal value of DKK 1, all in the same share class. The number of outstanding shares of the Company are as follows: 2021 2020 2019 2018 2017 Changes in share capital At January 1 53,750,386 47,985,837 42,135,448 36,984,292 32,421,121 Increase through cash contributions 3,187,296 5,764,549 5,850,389 5,151,156 4,563,171 At December 31 56,937,682 53,750,386 47,985,837 42,135,448 36,984,292 Treasury Shares Reserve On September 29, 2021, the Company’s Board of Directors authorized the Company to repurchase up to $25 million of the Company’s ADSs, each of which represents one ordinary share of Ascendis Pharma A/S (the “Share Repurchase Program”). The program was executed under Rules 10b-18 10b5-1 deposits and ended on November 9, 2021. The holding of treasury shares are as follows: Nominal Holding Holding in (EUR’000) (Number) Treasury shares At January 1, 2021 — — — Acquired from third-parties 21 154,837 — At December 31, 2021 21 154,837 0.3% Financial Risk Management Objectives The Company regularly monitors the access to domestic and international financial markets, manages the financial risks relating to its operations, and analyze exposures to risk, including market risk, such as foreign currency risk and interest rate risk, credit risk and liquidity risk. The Company’s financial risk exposure and risk management policies are described in the following sections. Market Risk The Company’s activities expose the group enterprises to the financial risks of changes in foreign currency exchange rates and interest rates. Derivative financial instruments are not applied to manage exposure to such risks. Foreign Currency Risk Management The Company is exposed to foreign currency exchange risks arising from various currency exposures, primarily with respect to the U.S. Dollar (“USD”), the British Pound (“GBP”) and Foreign currency exchange risks are unchanged to prior year, and primarily relate to purchases in foreign currencies, and cash, cash equivalents and marketable securities, denominated in USD. The exposure from foreign currency exchange risks is managed by maintaining cash positions in the currencies in which the majority of future expenses are denominated, and payments are made from those reserves. Foreign Currency Sensitivity Analysis The following table details how a strengthening of the USD and the GBP would impact profit and loss and equity before tax at the reporting date. A similar weakening of the USD and the GBP would have the opposite effect with similar amounts. A positive number indicates an increase in profit or loss and equity before tax, while a negative number indicates the opposite. The sensitivity analysis is deemed representative of the inherent foreign currency exchange risk associated with the operations. Nominal Hypothetical impact on consolidated Increase in Profit and Equity (EUR ‘000) December 31, 2021 USD/EUR 549,243 10% 54,924 54,924 GBP/EUR 6,686 10% 669 669 December 31, 2020 USD/EUR 797,927 10% 79,793 79,793 GBP/EUR 1,555 10% 155 155 Interest Rate Risk Management The Company has no interest-bearing debt to third parties. In addition, since the Company holds no derivatives or financial assets and liabilities measured at fair value, the exposure to interest rate risk primarily relates to the interest rates for cash, cash equivalents and marketable securities. Future interest income from interest-bearing bank deposits and marketable securities may fall short of expectations due to changes in interest rates. Rate structure of marketable securities are specified below: December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by rate structure Fixed rate 323,176 322,556 175,757 175,732 Floating rate 17,975 17,968 16,975 16,972 Zero-coupon 2,207 2,207 56,826 56,826 Total marketable securities 249,558 249,530 The effects of interest rate fluctuations are not considered a material risk to the Company’s financial position. Accordingly, no interest sensitivity analysis has been presented. Credit Risk Management The Company has adopted an investment policy with the primary purpose of preserving capital, fulfilling liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. This investment policy establishes minimum ratings for institutions with which the Company holds cash, cash equivalents and marketable securities, as well as rating and concentration limits for marketable securities held. All material counterparties are considered creditworthy. While the concentration of credit risk may be significant, the credit risk for each individual counterpart is considered to be low. The exposure to credit risk primarily relates to cash, cash equivalents, and marketable securities. The credit risk on bank deposits is limited because the counterparties, holding significant deposits, are banks with high credit-ratings (minimum A3/A-) Marketable securities specified by investment grade credit rating are specified below: December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by investment grade credit rating Prime — — 7,716 7,714 High grade 144,307 144,030 142,339 142,352 Upper medium grade 196,909 196,566 99,503 99,464 Lower medium grade 2,142 2,135 — — Total marketable securities 343,358 342,731 249,558 249,530 At the reporting dates, there are no significant overdue trade receivable balances. As a result, write-down to accommodate expected credit-losses is not deemed material. Liquidity Risk Management Historically, the risk of insufficient funds has been addressed through proceeds from sale of the Company’s securities in private and public offerings. Liquidity risk is managed by maintaining adequate cash reserves and banking facilities, and by matching the maturity profiles of marketable securities with cash-forecasts. The risk of shortage of funds is monitored, using a liquidity planning tool, to ensure sufficient funds are available to settle liabilities as they fall due. Besides marketable securities and deposits, the Company’s financial assets are recoverable within twelve months after the reporting date. The composition of the marketable securities portfolio and its fair values are specified in the following table. December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by security type U.S. Treasury bills — — 46,243 46,245 U.S. Government bonds 95,408 95,211 62,088 62,101 Commercial papers 2,207 2,207 10,583 10,581 Corporate bonds 226,771 226,379 121,282 121,234 Agency bonds 18,972 18,934 9,362 9,369 Total marketable securities 343,358 342,731 249,558 249,530 Classified based on maturity profiles Non-current 107,561 107,175 115,280 115,277 Current assets 235,797 235,556 134,278 134,253 Total marketable securities 343,358 342,731 249,558 249,530 Fair values are based on quoted market prices or for marketable securities with short-term and infrequent market trades on mathematical calculations applying observable inputs (Level 1 or 2 in the fair value hierarchy). Marketable securities have a weighted average duration of 5.8 and 16.7 months, for current (i.e., those maturing within twelve months after the reporting date) and non-current non-current) Maturity analysis Maturity analysis for financial liabilities recognized in the consolidated statements of financial position are specified below. < 1 year 1-5 years >5 years Total Carrying (EUR’000) December 31, 2021 Lease liabilities 7,098 51,442 68,378 126,918 104,961 Trade payables and accrued expenses 59,417 — — 59,417 59,417 Total financial liabilities 66,515 51,442 68,378 186,335 164,378 < 1 year 1-5 years >5 years Total Carrying (EUR’000) December 31, 2020 Lease liabilities 6,974 38,321 68,516 113,811 91,975 Trade payables and accrued expenses 21,897 — — 21,897 21,897 Total financial liabilities 28,871 38,321 68,516 135,708 113,872

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Related Party Transactions	Note 18—Related Party Transactions The Board of Directors, the Non-executive Neither the Company’s related parties or major shareholders hold a controlling, joint controlling, or significant interest in the Group. The Company has entered into employment agreements with and issued warrants and RSUs to Key Management Personnel. In addition, the Company pays fees for board tenure and board committee tenure to the independent members of the Board of Directors. For further details, refer to Note 7 “Employee Cost”. Indemnification agreements have been entered with members of the Board of Directors, the Executive Board and Non-executive Senior Management. Transactions between the parent company and group enterprises comprise management and license fees, research and development services, and clinical and commercial supplies. These transactions have been eliminated in the consolidated financial statements. Transactions and outstanding balances with the associate are disclosed in Note 12 “Investment in Associate”. In addition, the parent company Ascendis Pharma A/S is jointly taxed with its Danish subsidiaries, where the current Danish corporation tax is allocated between the jointly taxed Danish companies. For further details, refer to Note 9 “Tax on Profit/(Loss) for the Year and Deferred Tax”. Except for the information disclosed above, the Company has not undertaken any significant transactions with members of the Key Management Personnel, or undertakings in which the identified related parties have a controlling or joint controlling interest.

Investments in Group Enterprise

Investments in Group Enterprises	12 Months Ended
	Dec. 31, 2021
Investments In Group Enterprises [Abstract]
Investments in Group Enterprises	Note 19—Investments in Group Enterprises Ascendis Pharma A/S’s (parent company) investments in group enterprises at December 31, 2021, comprise: Subsidiaries Domicile Ownership Ascendis Pharma GmbH Germany 100% Ascendis Pharma, Inc. USA 100% Ascendis Pharma Endocrinology, Inc. USA 100% Ascendis Pharma Ophthalmology Division A/S Denmark 100% Ascendis Pharma Endocrinology Division A/S Denmark 100% Ascendis Pharma Bone Diseases A/S Denmark 100% Ascendis Pharma Growth Disorders A/S Denmark 100% Ascendis Pharma Oncology Division A/S Denmark 100% Associate Domicile Ownership VISEN Pharmaceuticals Cayman Island 43.93%

Ownership

Ownership	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Ownership	Note 20—Ownership The following investors, or groups of affiliated investors, are known by us to beneficially own more than 5% of the Company’s outstanding ordinary shares at December 31, 2021: • T. Rowe Price Associates, Inc., USA • Entities affiliated with RA Capital Management, LLC, USA • Entities affiliated with Artisan Partners Limited Partnership, USA • Entities affiliated with FMR LLC, USA • Baker Bros. Advisors LP, USA • Entities affiliated with Wellington Management Group LLP, USA • Entities affiliated with Janus Henderson Group plc, United Kingdom The Company’s American Depository Shares are held through BNY (Nominees) Limited as nominee, of The Bank of New York Mellon, UK (as registered holder of the Company’s outstanding ADSs).

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Subsequent Events	Note 21—Subsequent Events In February 2022, the Company entered into a facility lease in Germany with an enforceable lease term of 15 years, which is expected to commence in 2025. Subject to terms and conditions and development in interest rates, an initial lease liability and corresponding right-of-use No other events have occurred after the reporting date that would influence the evaluation of these consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Basis of Preparation	Basis of Preparation The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”), and as adopted by the European Union (“EU”). The accounting policies applied when preparing the consolidated financial statements are described in detail below and are applied for all entities. Significant accounting judgements and sources of estimation uncertainties used when exercising the accounting policies are described in Note 3 “Significant Accounting Judgements and Estimates”. These consolidated financial statements have been prepared under the historical cost convention, apart from certain financial instruments that are measured at fair value at initial recognition.
Changes in Accounting Policies and Disclosures	Changes in Accounting Policies and Disclosures Several amendments to and interpretations of IFRS applied for the first time in 2021, which has not had an impact on the accounting policies applied by the Company. Thus, the accounting policies applied when preparing these consolidated financial statements have been applied consistently to all the periods presented.
Going Concern	Going Concern The Company’s Board of Directors has, at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the Company continues to adopt the going concern basis of accounting in preparing the consolidated financial statements.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the parent company, Ascendis Pharma A/S, and all enterprises over which the parent company has control. Control of an enterprise exists when the Company has exposure, or rights to, variable returns from its involvement with the enterprise and has the ability to control those returns through its power over the enterprise. Accordingly, the consolidated financial statements include Ascendis Pharma A/S and the subsidiaries listed in Note 19 “Investment in Group Enterprises”.
Consolidation Principles	Consolidation Principles Subsidiaries, which are enterprises the Company control at the reporting date, are fully consolidated from the date upon which control is transferred to the Company. They are deconsolidated from the date control ceases. Control over an enterprise is reassessed if facts and circumstances indicate that there are changes to one or more of the three elements of control, respectively: • The contractual arrangement(s) with the other vote holders of the enterprise; • The Company’s voting rights and potential voting rights; and • Rights arising from other contractual arrangements. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between group enterprises are eliminated in full on consolidation. Subsidiaries apply accounting policies in line with the Company’s accounting policies. When necessary, adjustments are made to bring the entities’ accounting policies in line with those of the Company. Investment in Associates An associate is an entity over which the Company has significant influence over financial and operational decisions but without having control or joint control. The Company’s associate is accounted for using the equity method. Under the equity method, the associate is initially recognized at cost. Thereafter, the carrying amount of the investment is adjusted to recognize changes in the Company’s share of net assets of the associate since the acquisition or establishment date. The consolidated statements of profit or loss include the Company’s share of result after tax of the associate after any adjustments made to bring the associates accounting policies in line with those of the Company. Transactions between the associate and the Company are eliminated proportionally according to the Company’s interest in the associate. Unrealized gains and losses resulting from transactions between the Company and its associate is eliminated to the extent of the Company’s interest in the associate. On each reporting date, the Company determines whether there is objective evidence that the associate is impaired. If there is such evidence, the amount of impairment is calculated as the difference between the recoverable amount of the associate and its carrying amount. Any impairment loss is recognized in the consolidated statements of profit or loss.
Foreign Currency	Foreign Currency Functional and Presentation Currency Items included in the consolidated financial statements are measured using the functional currency of each group entity. Functional currency is the currency of the primary economic environment in which the entity operates. The consolidated financial statements are presented in Euros (“EUR”), which is also the functional currency of the parent company. Translation of Transactions and Balances On initial recognition, transactions in currencies other than the individual entity’s functional currency are translated applying the exchange rate in effect at the date of the transaction. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the reporting date are translated using the exchange rate in effect at the reporting date. Exchange rate differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the reporting date, are recognized in profit or loss as finance income or finance expenses. Property, plant and equipment, intangible assets and other non-monetary Currency Translation of Group Enterprises When subsidiaries or associates present their financial statements in a functional currency other than EUR, their statements of profit or loss are translated at average exchange rates. Balance sheet items are translated using the exchange rates at the reporting date. Exchange rate differences arising from translation of foreign entities’ balance sheet items at the beginning of the year to the reporting date exchange rates as well as from translation of statements of profit or loss from average rates to the exchange rates at the reporting date are recognized in other comprehensive income. Similarly, exchange rate differences arising from changes that have been made directly in a foreign subsidiary’s equity are recognized in other comprehensive income.
Business Combinations	Business Combinations Newly acquired or newly established subsidiaries are recognized in the consolidated financial statements from the time of acquiring or establishing such enterprises. Time of acquisition is the date on which the Company obtains control over the enterprise. When acquiring new enterprises over which the Company obtains control, the acquisition method is applied. Under this method, assets, liabilities and contingent liabilities of these enterprises are identified and measured at fair value as of the acquisition date. Restructuring costs are only recognized in the pre-acquisition The acquisition price for an enterprise consists of the fair value of the consideration paid for the acquired enterprise. Costs that are attributable to the acquisition of the enterprise are recognized in the consolidated statement of profit or loss when incurred. The excess of the consideration transferred, the amount of any non-controlling Goodwill is subject to an annual impairment test. Impairment is calculated as the difference between the recoverable amount of the cash-generating unit that the goodwill relates to, and its carrying amount. Any impairment loss is recognized in the consolidated statement of profit or loss in a separate line item.
Revenue	Revenue Revenue from Commercial Sale of Products Revenue is recognized when the customer has obtained control of the goods and it is probable that the Company will collect the consideration to which it is entitled for transferring the goods. Control is transferred upon delivery. Revenue is measured at the contractual sales price, reflecting the consideration received or receivable from customers, net of value added taxes, and provisions for a variety of sales deductions including prompt pay discounts, shelf stock adjustments and applicable sales rebates attributed to various commercial arrangements, managed healthcare organizations, and government programs such as Medicaid and the 340B Drug Pricing Program (chargebacks), and co-pay “sale-or-return” Unsettled sales rebates and product returns are recognized as provisions when timing or amount is uncertain. Payable amounts that are absolute are recognized as other liabilities. Sales discounts and rebates that are payable to customers are off-set Other Revenue Other revenue is primarily generated from collaboration and license agreements. In addition, other revenue is generated from feasibility studies for potential partners to evaluate if TransCon technologies enable certain advantages for their product candidates of interest. Such feasibility studies are often structured as short-term agreements with fixed fees for the work that the Company performs. When contracts with customers are entered into, the goods and/or services promised in the contract are assessed to identify distinct performance obligations. A promise in the agreement is considered a distinct performance obligation if both of the following criteria are met: • the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (i.e., the good or service is capable of being distinct); and • the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (i.e., the promise to transfer the good or service is distinct within the context of the contract). Under collaboration, license, and other agreements that contain multiple promises to the customer, the promises are identified and accounted for as separate performance obligations if these are distinct. If promises are not distinct, those goods or services are combined with other promised goods or services until a bundle of goods or services that is distinct is identified. The transaction price in the contract is measured at fair value and reflects the consideration the Company expects to be entitled to in exchange for those goods or services. In the transaction price, variable consideration, including milestone payments, is only included to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The transaction price is allocated to each performance obligation according to their stand-alone selling prices and is recognized when control of the goods or services are transferred to the customer, either over time or at a point in time, depending on the specific terms and conditions in the contracts. Other revenue is stated net of value added taxes, and discounts.
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of manufacturing costs, preclinical and clinical study costs and costs for process optimizations and improvements performed by Clinical Research Organizations (“CROs”) and Contract Manufacturing Organizations (“CMOs”), salaries and other personnel costs including pension and share-based payment, the cost of facilities, professional fees, cost of obtaining and maintaining the Company’s intellectual property portfolio, and depreciation of non-current Research costs are incurred at the early stages of the drug development cycle from the initial drug discovery and include a variety of preclinical research activities in order to assess potential drug candidates in non-human Development activities relate to activities following an IND, or equivalent, and typically involves a single product candidate undergoing a series of studies to illustrate its safety profile and effect on human beings prior to obtaining the necessary approval from the appropriate authorities. Development activities comprise drug candidates undergoing clinical trials starting in phase I (first time drug is administrated in a small group of humans), and further into Phase II and III, which include administration of drugs in large patient groups. Following, and depending on clinical trial results, a Biologic License Application (“BLA”) may be submitted to the authorities, to apply for marketing approval, which, with a positive outcome will permit the Company to market and sell the drug products. Long-term extension trials may be ongoing following submission of a BLA. Development costs also include manufacturing costs related to validation batches, or process performance qualification batches on development product candidates, and write-downs of inventories manufactured for late-stage development product candidates prior to marketing approval being obtained (pre-launch Due to the risk related to the development of pharmaceutical products, the Company cannot estimate the future economic benefits associated with individual development activities with sufficient certainty until the development activities have been finalized and the necessary market approval of the final product has been obtained. As a consequence, all development costs are recognized in the consolidated statement of profit or loss when incurred.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses Selling, general and administrative expenses comprise salaries and other personnel costs including pension and share-based payment, office supplies, cost of facilities, professional fees, and depreciation of non-current
Share-based Incentive Programs	Share-based Incentive Programs Share-based incentive programs comprise warrant programs and Restricted Stock Unit programs (“RSU-programs”) The cost of equity-settled transactions is determined by the fair value at the date of grant. For warrant programs, the fair value of each warrant granted is determined using the Black-Scholes valuation model. For RSU-programs, The cost is recognized together with a corresponding increase in equity over the period in which the performance and/or service conditions are fulfilled (i.e., the vesting period). The fair value determined at the grant date of the equity-settled share-based payment is expensed on a straight-line basis over the vesting period for each tranche, based on the best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for grants that do not ultimately vest. Where an equity-settled grant is cancelled other than upon forfeiture when vesting conditions are not satisfied, the grant is treated as if it vested on the date of the cancellation, and any expense not yet recognized for the grant is recognized immediately. Where the terms and conditions for an equity-settled grant is modified, the services measured at the grant date fair value over the vesting period are recognized, subject to performance and/or service conditions that was specified at the initial grant date(s). Additionally, at the date of modification, unvested grants are re-measured Any social security contributions payable in connection with the grant or exercise of the warrants are recognized as expenses when incurred. The assumptions used for estimating the fair value of share-based payment transactions are disclosed in Note 7 “Share-based Payment”.
Finance Income and Expenses	Finance Income and Expenses Finance income and expenses comprise interest income and expenses and realized and unrealized exchange rate gains and losses on transactions denominated in foreign currencies. Interest income and interest expenses are stated on an accrual basis using the principal and the effective interest rate. The effective interest rate is the discount rate that is used to discount expected future cash payments or receipts through the expected life of the financial asset or financial liability to the amortized cost (the carrying amount) of such asset or liability.
Income Taxes	Income Taxes Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognized in the consolidated statement of profit or loss by the portion attributable to the profit or loss for the year and recognized directly in equity or other comprehensive income by the portion attributable to entries directly in equity and in other comprehensive income. The current tax payable or receivable is recognized in the consolidated statement of financial position, stated as tax computed on this year’s taxable income, adjusted for prepaid tax. When computing the current tax for the year, the tax rates and tax rules enacted or substantially enacted at the reporting date are used. Current tax payable is based on taxable profit or loss for the year. Taxable profit or loss differs from net profit or loss as reported in the consolidated statements of profit or loss because it excludes items of income or expense that are taxable or deductible in prior or future years. In addition, taxable profit or loss excludes items that are never taxable or deductible. Deferred tax is recognized according to the balance sheet liability method of all temporary differences between carrying amounts and tax-based Deferred tax liabilities are recognized on all temporary differences related to investments in subsidiaries and/or associates, unless the Company is able to control when the deferred tax is realized, and it is probable that the deferred tax will not become due and payable as current tax in the foreseeable future. Deferred tax assets, including the tax base of tax loss carry forwards, are recognized in the statement of financial position at their estimated realizable value, either as a set-off Deferred tax is measured using the tax rates and tax rules in the relevant countries that, based on acts in force or acts in reality in force at the reporting date are expected to apply when the deferred tax is expected to crystallize as current tax. Changes in deferred tax resulting from changed tax rates or tax rules are recognized in the consolidated statement of profit or loss unless the deferred tax is attributable to transactions previously recognized directly in equity or other comprehensive income. In the latter case, such changes are also recognized in equity or other comprehensive income. On every reporting date, it is assessed whether sufficient taxable income is likely to arise in the future for the deferred tax asset to be utilized.
Intangible assets	Intangible assets Goodwill Goodwill acquired in a business combination is initially measured at cost, being the excess of the aggregate of the consideration transferred and the amount recognized for non-controlling After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is not amortized but is subject to impairment testing at least on a yearly basis. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or group of cash-generating units, that are expected to benefit from the synergies of the combination. Each cash-generating unit or group of cash-generating units to which goodwill is allocated represent the lowest level within the Company at which the goodwill is monitored for internal management purposes.
Software	Software Software assets comprise administrative applications and serve general purposes to support the Company’s operations. Development costs that are directly attributable to the design, customization, implementation, and testing of identifiable and unique software assets controlled by the Company are recognized as intangible assets from the time that; (1) the software asset is clearly defined and identifiable; (2) technological feasibility, adequate resources to complete, and an internal use of the software asset can be demonstrated; (3) the expenditure attributable to the software asset can be measured reliably; and (4) the Company has the intention to use the software asset internally. The Company does not capitalize software with no alternative use, or where economic benefit depends on marketing approvals of drug candidates and where marketing approvals have not been obtained. Following initial recognition of the development expenditure as an asset, the asset is carried at cost less any accumulated amortization and accumulated impairment losses. Amortization of the asset begins when the development is complete, and the asset is available for use. Software assets are amortized over the period of expected future benefits. Amortization is recognized in research and development costs, and selling, general and administrative expenses, as appropriate. During the period of development, the asset is tested for impairment, at least annually, or if there are indications that the asset is impaired. Expenditures, that do not meet the criteria above are recognized as an expense as incurred.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment primarily comprises leasehold improvements, office facilities, and process equipment and tools which are located at CMOs. Property, plant and equipment also includes right-of-use Property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Cost comprises the acquisition price, costs directly attributable to the acquisition and preparation costs of the asset until the time when it is ready to be used in operation. Subsequent costs are included in the carrying amount of the asset or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the assets will flow to the Company and the costs of the items can be measured reliably. All repair and maintenance costs are charged to the consolidated statement of profit or loss during the financial periods in which they are incurred. Plant and equipment acquired for research and development activities with alternative use, which is expected to be used for more than one year, is capitalized and depreciated over the estimated useful life as research and development costs. Plant and equipment acquired for research and development activities, which has no alternative use, is recognized as research and development costs when incurred. If the acquisition or use of the asset involves an obligation to incur costs of decommissioning or restoration of the asset, the estimated related costs are recognized as a provision and as part of the relevant asset’s cost, respectively. The basis for depreciation is cost less estimated residual value. The residual value is the estimated amount that would be earned if selling the asset today net of selling costs, assuming that the asset is of an age and a condition that is expected after the end of its useful life. Cost of a combined asset is divided into smaller components, with such significant components depreciated individually if their useful lives vary. Depreciation commences when the asset is available for use, which is when it is in the location and condition necessary for it to be capable of operating in the manner intended. Depreciation is calculated on a straight-line basis, based on an asset’s expected useful life, being within the following ranges: Process plant and machinery 5 - 10 years Other equipment 3 - 5 years Leasehold improvements 3 - 11 years Right-of-use 2 - 11 years Depreciation methods, useful lives and residual amounts are reassessed at least annually. Property, plant and equipment is written down to the lower of recoverable amount and carrying amount, as described in the “Impairment” section below. Depreciation and impairment losses of property, plant and equipment is recognized in the consolidated statement of profit or loss as cost of sales, research and development costs or as selling, general and administrative expenses, as appropriate. Gains and losses on disposal of property, plant and equipment are recognized in the consolidated statement of profit or loss at its net proceeds, as either other operating income or other operating expenses, as appropriate.
Impairment	Impairment The recoverable amount of goodwill and development projects in progress (software assets) is estimated annually irrespective of any recorded indications of impairment. Property, plant and equipment and finite-lived intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows, or cash-generating units, which for goodwill represent the lowest level within the enterprise at which the goodwill is monitored for internal management purposes. Prior impairments of non-financial
Inventories	Inventories Inventories comprise raw materials, work in progress and finished goods. Work in progress and finished goods comprise service expenses incurred at CMOs, raw materials consumed, incremental storage and transportation, other direct materials, and a proportion of manufacturing overheads based on normal operation capacity. Inventories are measured at the lower of cost incurred in bringing it to its present location and condition, and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale. Production processes are complex, where actual yields and consumptions are sensitive to a wide variety of manufacturing conditions. Work in progress and finished goods are measured under a standard cost method that takes into account normal levels of consumption, yields, labor, efficiency and capacity utilization. Standard cost variances are reviewed regularly and adjusted to ensure inventories approximate actual cost of production. If net realizable value is lower than cost, a write-down is recognized as the excess amount by which cost exceeds net realizable value, as part of cost of sales when incurred. The amount of reversal of write-down of inventories arising from an increase in net realizable value is recognized as a reduction in cost of sales in the period in which the reversal occurs. Manufacturing of pre-launch pre-launch pre-launch pre-launch Cost of inventories is recognized as part of cost of sales in the period in which the related revenue is recognized.
Receivables	Receivables Receivables comprise trade receivables, income tax receivables and other receivables. Trade receivables are classified as financial assets at amortized cost, as these are held to collect contractual cash flows and thus give rise to cash flows representing solely payments of principal and interest. Trade receivables are initially recognized at their transaction price and subsequently measured at amortized cost. Income tax receivables, and other receivables related to deposits, VAT and other indirect taxes are measured at cost less impairment. Carrying amounts of receivables usually equals their nominal value less provision for impairments.
Prepayments	Prepayments Prepayments comprise advance payments relating to a future financial period. Prepayments are measured at cost.
Marketable Securities	Marketable Securities Marketable securities may comprise government bonds, treasury bills, commercial papers, and other securities traded on established markets. At initial recognition (trade-date), contractual terms of individual securities are analyzed to determine whether these give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding. This assessment is referred to as the SPPI-test. All marketable securities held at the reporting date have passed the SPPI-test. Marketable securities are initially recognized at fair value at trade-date, and subsequently measured at amortized cost under the effective interest method. Interest income is recognized as finance income in the consolidated statement of profit or loss. Marketable securities are subject to impairment test to accommodate expected credit loss. Gains and losses are recognized as finance income or expenses in the consolidated statement of profit or loss when the specific security or portfolio of securities is derecognized, modified or impaired. Marketable securities, having maturity profiles of three months or less after the date of acquisition are presented as cash equivalents in the consolidated statements of financial position, where securities having maturities of more than three months after the date of acquisition are presented separately as marketable securities as current (i.e., those maturing within twelve months after the reporting date) or non-current
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents comprise cash and on-demand
Allowance for Expected Credit Losses on Financial Assets	Allowance for Expected Credit Losses on Financial Assets Financial assets comprise receivables (excluding receivables relating to VAT, other indirect tax and income tax), marketable securities and cash and cash equivalents. Impairment of financial assets is determined on the basis of a forward-looking Expected Credit Loss (“ECL”) Model. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and the cash flows expected to be received, discounted by an approximation of the original effective interest rate. For receivables, a simplified approach in calculating ECLs is applied. Therefore, changes in credit risks are not tracked, but instead, a loss allowance based on lifetime ECL is assessed at each reporting date. Lifetime ECLs are assessed on historical credit loss experience, adjusted for forward-looking factors specific to the counterparts and the economic environment. For cash, cash equivalents and marketable securities, ECLs are assessed for credit losses that result from default events that are possible within the next twelve months (12-month ECL). Credit risk is continuously tracked and monitored in order to identify significant deterioration. For those credit exposures for which there have been a significant increase in credit risk since initial recognition, an allowance is recognized for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default.
Shareholders' Equity	Shareholders’ Equity The share capital comprises the nominal amount of the parent company’s ordinary shares, each at a nominal value of DKK 1, or approximately €0.13. All shares are fully paid. Share premium comprises the amounts received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the parent company’s capital increases, reduced by any expenses directly attributable to the capital increases. Under Danish legislation, share premium is an unrestricted reserve that is available to be distributed as dividends to a company’s shareholders. Also, under Danish legislation, the share premium reserve can be used to offset accumulated deficits. Treasury shares reserve comprise own equity instrument which are recognized at cost and included within equity. No gain or loss is recognized in profit or loss on the purchase, sale, transfer or cancellation of the Company’s own equity instruments. The treasury shares reserve is part of unrestricted reserves and accordingly, reduce the amount available to be distributed as dividends to the Company’s shareholders. Foreign currency translation reserve includes exchange rate adjustments relating to the translation of the results and net assets of foreign operations from their functional currencies to the presentation currency. The accumulated reserve of a foreign operation is reclassified to the consolidated statement of profit or loss at the time the Company loses control, and thus cease to consolidate such foreign operation. The foreign currency translation reserve is an unrestricted reserve that is available to be distributed as dividends to the Company’s shareholders. Share-based payment reserve represents the corresponding entries to the share-based payment recognized in the consolidated statement of profit or loss, arising from warrant programs and restricted stock units programs. The share-based payments reserve is an unrestricted reserve that is available to be distributed as dividends to the Company’s shareholders. Retained earnings/(accumulated deficit) represents the accumulated profits or losses from the Company’s operations. A positive reserve is available to be distributed as dividends to the Company’s shareholders.
Leases	Leases Right-of-use Right-of-use Right-of-use right-of-use right-of-use Right-of-use Lease Liabilities At the lease commencement date, lease liabilities are recognized and measured at the present value of fixed lease payments and variable lease payments that depend on an index or a rate, whereas variable lease payments and payments related to non-lease When interest rates implicit in the lease contracts are not readily available, the present value of lease payments are calculated by applying the incremental borrowing rate of the relevant entity holding the lease. Following the commencement date, the incremental borrowing rate is not changed unless the lease term is modified, or if the lease payments are modified and this modification results from a change in floating interest rates. From the lease commencement date and over the lease term, the carrying amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in lease term, or a change in lease payments, including changes to future payments resulting from a change in an index used to determine such lease payments.
Provisions	Provisions Provisions comprise unsettled sales reductions and product returns regarding sale of commercial products where amount or timing of payment is uncertain. Provisions for commercial sales rebates, attributed to various commercial arrangements, managed healthcare organizations, and government programs such as Medicare, Medicaid and the 340B Drug Pricing Program (“chargebacks”), and co-pay 90-180 Provisions for estimated product returns are measured according to contractual sales price based on expected product returns.
Trade Payables and Accrued Expenses	Trade Payables and Accrued Expenses Trade payables and accrued expenses are measured at amortized cost.
Other Liabilities	Other Liabilities Other liabilities comprise payables to public authorities, short-term employee benefits, and sales rebates. Other liabilities are measured at their net-realizable
Contract Liabilities	Contract Liabilities Contract liabilities comprise deferred income from collaboration and license agreements, where consideration received does not match the individual deliverables with respect to amount and satisfied performance obligations. Contract liabilities are
Cash Flow Statement	Cash Flow Statement The cash flow statement shows cash flows from operating, investing and financing activities as well as cash and cash equivalents at the beginning and the end of the financial year. Cash flows from operating activities are presented using the indirect method and calculated as the profit or loss adjusted for non-cash Cash flows from investing activities include payments in connection with acquisitions, development, improvement and sale, etc., of intangible assets, property, plant and equipment, group enterprises and associate. In addition, investing activities include acquisition and settlement of marketable securities. Cash flows from financing activities comprise payments related to lease liabilities, and changes in the share capital and treasury shares of Ascendis Pharma A/S and related costs. The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency is presented separately from cash flows from operating, investing and financing activities. Cash flows in currencies other than the functional currency are recognized in the cash flow statement, using the average exchange rates. Cash and cash equivalents comprise cash and on-demand
Basic EPS	Basic Earnings per Share Basic Earnings per Share (“EPS”) is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding. The weighted average number of shares takes into account the weighted average effect of changes in treasury shares during the year.
Diluted EPS	Diluted Earnings per Share Diluted EPS is calculated as the consolidated net income or loss from continuing operations for the period divided by the weighted average number of ordinary shares outstanding adjusted for the weighted average effect of changes in treasury shares during the year, and the dilutive effect of outstanding warrants. If the consolidated statement of profit or loss shows a net loss, no adjustment is made for the dilutive effect, as such effect would be anti-dilutive.
New International Financial Reporting Standards Not Yet Effective	New International Financial Reporting Standards Not Yet Effective The IASB has issued, and the EU has adopted, a number of new or amended standards, which have not yet become effective. Therefore, these new standards have not been incorporated in these consolidated financial statements. The consolidated financial statements are not expected to be affected by such new or improved standards.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Schedule of Asset's Expected Useful Life	Depreciation is calculated on a straight-line basis, based on an asset’s expected useful life, being within the following ranges: Process plant and machinery 5 - 10 years Other equipment 3 - 5 years Leasehold improvements 3 - 11 years Right-of-use 2 - 11 years

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Schedule of Revenue Recognized in Consolidated Statement of Profit or Loss	Revenue has been recognized in the consolidated statements of profit or loss with the following amounts: 2021 2020 2019 (EUR’000) Revenue from external customers Commercial sale of products 943 — — Rendering of services 751 2,140 9,919 Sale of clinical supply 3,719 2,206 804 “Right-to-use” 2,365 2,607 2,652 Total revenue 7,778 6,953 13,375 Attributable to Commercial customers 943 — — Collaboration partners and license agreements (1) 6,835 6,953 13,375 Total revenue 7,778 6,953 13,375 Specified by timing of recognition Recognized over time 751 2,140 9,919 Recognized at a point in time 7,027 4,813 3,456 Total revenue 7,778 6,953 13,375 Specified per geographical location North America 6,856 2,679 2,652 China 922 4,274 10,723 Total revenue 7,778 6,953 13,375 (1) Revenue from collaboration partners and license agreements includes recognition of previously deferred revenue/internal profit from associate of €2.4 million, €3.5 million and €6.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. Revenue from one collaboration partner amounted to 95 % of total revenue from collaboration partners and license agreements.

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Disclosure of intangible assets, and property, plant and equipment	The Company’s intangible assets and property, plant and equipment located by country are specified below, and defines the Company’s non-current 2021 2020 (EUR’000) Non-current Denmark (domicile country) 29,656 20,288 North America 91,755 85,476 Germany 9,910 8,065 Total non-current 131,321 113,829 Investment in associate 38,345 9,176 Marketable securities 107,561 115,280 Other receivables 1,808 1,375 Total non-current 279,035 239,660

Employee Cost (Tables)

Employee Cost (Tables)	12 Months Ended
	Dec. 31, 2021
Statement [LineItems]
Summary of Employee Cost	2021 2020 2019 (EUR’000) Employee costs Wages and salaries 104,583 77,374 49,142 Share-based payment 66,830 53,170 37,486 Pensions (defined contribution plans) 2,416 943 648 Social security costs 4,571 5,358 3,613 Total employee costs 178,400 136,845 90,889 Included in the profit or loss — — — Cost of sales 1,380 — — Research and development costs 106,558 92,468 61,890 Selling, general and administrative expenses 70,462 44,377 28,999 Total employee costs 178,400 136,845 90,889 Average number of employees 573 410 274
Key management personnel of entity or parent [member]
Statement [LineItems]
Summary of Employee Cost	Compensation to Key Management Personnel included within total employee costs is summarized below: Board of Directors (1) Executive Board (2) Non-executive 2021 2020 2019 2021 2020 2019 2021 2020 2019 (EUR ‘000) Compensation Wages and salaries 296 250 265 2,699 2,372 1,815 5,547 5,272 4,706 Share-based payment 2,032 1,913 1,864 8,770 6,359 5,303 14,906 13,912 11,123 Pensions (defined contribution plans) — — — 23 — — 120 89 54 Social security costs — — — 49 100 94 60 122 84 Total compensation 2,328 2,163 2,129 11,541 8,831 7,212 20,633 19,395 15,967 (1) The Board of Directors comprised six to seven persons in 2021. At December 31, 2021, the Board of Directors comprised six persons. For 2020 and 2019, the Board of Directors comprised seven persons. (2) The Executive Board comprised two to four persons in 2021. At December 31, 2021, the Executive Board comprised four persons. For 2020 and 2019, the Executive Board comprised two persons.

Share-based Payment (Tables)

Share-based Payment (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary Of Share Based Payment	RSUs were granted for the first time in December 2021. The following table specifies the number of RSUs granted, their fair value at grant date, and outstanding RSUs at December 31, 2021: Total Outstanding at January 1, 2021 — — Granted, December 2021 148,148 123.46 Outstanding at December 31, 2021 148,148 123.46 Vested at the reporting date — —
Summary of Weighted Average Exercise Prices and Movements in Warrants	The following table specifies the number and weighted average exercise prices of, and movements, in warrants during the year: Total Weighted Outstanding at January 1, 2019 5,611,629 29.03 Granted during the year 1,300,600 97.01 Exercised during the year (1) (1,058,722 ) 16.33 Forfeited during the year (33,296 ) 58.49 Expired during the year — — Outstanding at December 31, 2019 5,820,211 46.36 Vested at the reporting date 2,705,693 24.93 Granted during the year 1,485,931 137.57 Exercised during the year (1) (905,395 ) 30.56 Forfeited during the year (252,743 ) 64.99 Expired during the year — — Outstanding at December 31, 2020 6,148,004 69.97 Vested at the reporting date 3,044,827 37.29 Granted during the year 1,445,981 122.03 Exercised during the year (1) (312,296 ) 38.43 Forfeited during the year (196,616 ) 119.58 Expired during the year — — Outstanding at December 31, 2021 7,085,073 80.30 Vested at the reporting date 4,022,011 52.63 (1) The weighted average share price (listed in $) at the date of exercise was €124.62, €128.32 and €108.54 for the years ended December 31, 2021, 2020 and 2019, respectively.
Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants	The following table specifies the weighted average exercise prices and weighted average remaining contractual life for outstanding warrants at December 31, 2021 per grant year. Number of Weighted Weighted Granted in 2012-2017 2,059,718 20.96 53 Granted in 2018 1,209,072 54.52 82 Granted in 2019 1,071,441 97.23 93 Granted in 2020 1,310,094 137.89 104 Granted in 2021 1,434,748 122.03 118 Outstanding at December 31, 2021 7,085,073 80.30 87
Summary of Fair Values for Warrant Grants	The following table summarizes the input to the Black-Scholes Option Pricing model and the calculated fair values for warrant grants in 2021, 2020 and 2019: 2021 2020 2019 Expected volatility 48 – 49% 52 – 55% 52 – 54% Risk-free interest rate (0.54)–(0.27)% (0.93)–(0.32)% (0.77)–(0.05)% Expected life of warrants (years) 6.0 5.05 – 7.10 5.05 – 7.10 Weighted average exercise price € 122.03 € 137.57 € 97.01 Fair value of warrants granted in the year € 45.91 – 64.28 € 48.43 – 75.77 € 27.24 – 55.64

Principal Accountant Fees and_2

Principal Accountant Fees and Services (Tables)	12 Months Ended
	Dec. 31, 2021
Auditor's remuneration [abstract]
Summary of Principal Accountant Fees and Services	The following table sets forth, for each of the years indicated, the fees billed by the Company’s independent public accountants and the proportion of each of the fees out of the total amount billed by the accountants. 2021 2020 2019 (EUR’000) Principal accountant fees and services Audit fees 771 599 700 Tax fees 87 104 7 All other fees 13 22 — Total principal accountant fees and services 871 725 707

Tax on Profit_(Loss) for the _2

Tax on Profit/(Loss) for the Year and Deferred Tax (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Tax on Profit/Loss and Deferred Tax	2021 2020 2019 (EUR’000) Tax on profit/(loss) for the year: Current tax (expense)/income 367 219 234 367 219 234 2021 2020 2019 (EUR’000) Tax for the year can be explained as follows: Profit/(loss) before tax (383,944 ) (419,174 ) (218,250 ) Tax at the Danish corporation tax rate of 22% 84,468 92,218 48,015 Tax effect of: Non-deductible (14,800 ) (11,815 ) (8,249 ) Additional tax deductions 17,117 24,564 10,875 Impact from associate 3,169 (1,326 ) (1,680 ) Other effects including effect of different tax rates 305 2,673 1,602 Deferred tax asset, not recognized (89,892 ) (106,095 ) (50,329 ) Tax on profit/(loss) for the year 367 219 234 Effective tax rate (0.10)% (0.05)% (0.11)% 2021 2020 2019 (EUR’000) Specification of Deferred Tax Assets Tax deductible losses 313,011 227,234 123,234 Other temporary differences 12,856 7,726 5,631 Deferred tax asset, not recognized (325,867 ) (234,960 ) (128,865 ) Total Deferred Tax Assets at December 31 0 0 0

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Goodwill and Software	Goodwill Software Total (EUR’000) Cost: At January 1, 2020 3,495 — 3,495 Additions — 2,222 2,222 Disposals — — — Foreign exchange translation — — — At December 31, 2020 3,495 2,222 5,717 Additions — — — Disposals — — — Foreign exchange translation — — — At December 31, 2021 3,495 2,222 5,717 Accumulated amortization and impairments: At January 1, 2020 — — — Amortization charge — — — Impairment charge — — — Disposals — — — Foreign exchange translation — — — At December 31, 2020 — — — Amortization charge — (445 ) (445 ) Impairment charge — — — Disposals — — — Foreign exchange translation — — — At December 31, 2021 — (445 ) (445 ) Carrying amount: At December 31, 2020 3,495 2,222 5,717 At December 31, 2021 3,495 1,777 5,272

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Property, Plant and Equipment	Plant and Other Leasehold Right-of-Use Total (EUR’000) Cost: At January 1, 2020 8,038 3,944 4,288 40,119 56,389 Additions 7,169 1,635 4,849 64,582 78,235 Disposals (296 ) (221 ) (14 ) (531 ) Foreign exchange translation (289 ) (183 ) (588 ) (5,135 ) (6,195 ) At December 31, 2020 14,622 5,175 8,535 99,566 127,898 Additions 2,810 3,386 8,780 10,812 25,788 Disposals (772 ) (10 ) — (1,040 ) (1,822 ) Foreign exchange translation 286 271 752 6,797 8,106 At December 31, 2021 16,946 8,822 18,067 116,135 159,970 Accumulated depreciation: At January 1, 2020 (3,971 ) (1,563 ) (558 ) (5,228 ) (11,320 ) Depreciation charge (1,030 ) (956 ) (605 ) (6,857 ) (9,448 ) Disposals 204 191 7 — 402 Foreign exchange translation 16 41 22 501 580 At December 31, 2020 (4,781 ) (2,287 ) (1,134 ) (11,584 ) (19,786 ) Depreciation charge (1,499 ) (1,200 ) (1,284 ) (10,963 ) (14,946 ) Disposals 772 10 — 1,040 1,822 Foreign exchange translation (19 ) (70 ) (70 ) (852 ) (1,011 ) At December 31, 2021 (5,527 ) (3,547 (2,488 ) (22,359 ) (33,921 ) Carrying amount: At December 31, 2020 9,841 2,888 7,401 87,982 108,112 At December 31, 2021 11,419 5,275 15,579 93,776 126,049
Summary of Depreciation Charges	Depreciation charges are specified below: 2021 2020 2019 (EUR’000) Depreciation charges Cost of sales 252 — — Research and development costs 10,102 7,311 5,282 Selling, general and administrative expenses 4,592 2,137 1,406 Total depreciation charges

Investment in Associate (Tables

Investment in Associate (Tables)	12 Months Ended
	Dec. 31, 2021
VISEN Pharmaceuticals [member]
Statement [LineItems]
Schedule of Financial Information of Investment in VISEN	The following table illustrates the summarized relevant financial information of VISEN: VISEN Pharmaceuticals Principal place of business China 2021 2020 (EUR’000) Statement of profit or loss Profit/(loss) for the year from continuing operations (69,283 ) (19,049 ) Total comprehensive income ( 69,306 ) (19,049 ) Statement of financial position Non-current 16,599 16,635 Current assets 130,825 20,373 Total assets 147,424 37,008 Equity 135,333 33,708 Non-current 1,545 152 Current liabilities 10,546 3,148 Total equity and liabilities 147,424 37,008 Company’s share of equity before eliminations 59,455 16,854 Elimination of internal profit and other equity method adjustments (21,110 ) (7,678 ) Company’s share of equity 38,345 9,176 Investment in associate at December 31 38,345 9,176 Present ownership at December 31 43.93% 50% Transactions and outstanding balances as of December 31 Sale of goods and services to associate 6,472 6,880 Trade receivables from associate 1,644 184 Contract liabilities 5,565 —

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Inventories Explanatory	2021 (EUR’000) Inventories Raw materials and consumables 2,248 Work in progress 68,865 Finished goods 4,292 Total inventories 75,405

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Summary of Development In Lease Liabilities	Development in lease liabilities are specified below: Beginning Cash payments Non-cash End of Payment of Payment Additions Accretion of Foreign (EUR’000) Lease liabilities December 31, 2021 91,975 (6,429 ) (1,326 ) 10,812 3,396 6,533 104,961 December 31, 2020 36,619 (4,781 ) (1,209 ) 64,582 1,617 (4,853 ) 91,975
Summary of Expenses, Relating To Lease Activities In The Consolidated Statements	The following expenses relating to lease activities are recognized in the consolidated statements of profit or loss: 2021 2020 2019 (EUR’000) Lease expense Depreciation 10,963 6,857 5,237 Expenses relating to short term leases and leases of low value assets 186 470 202 Lease interest 3,396 1,617 1,014 Total lease expenses 14,545 8,944 6,453

Financial Risk Management and_2

Financial Risk Management and Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2021
Text block [abstract]
Schedule of Financial Assets and Liabilities	Financial assets and financial liabilities comprise the following: 2021 2020 (EUR’000) Financial assets Trade receivables 2,200 387 Other receivables 12,276 2,251 Marketable securities 343,358 249,558 Cash and cash equivalents 446,267 584,517 Financial assets measured at amortized cost 804,101 836,713 Financial liabilities Lease liabilities 104,961 91,975 Trade payables and accrued expenses 59,417 21,897 Financial liabilities measured at amortized cost 164,378 113,872
Schedule of Finance Income and Finance Expenses	Finance income and expenses are specified below: 2021 2020 2019 (EUR’000) Finance income Interest income 692 1,812 10,056 Exchange rate gains 59,026 — 7,747 Total finance income 59,718 1,812 17,803 Finance expenses Interest expenses 3,911 1,918 1,221 Exchange rate losses — 78,924 — Total finance expenses 3,911 80,842 1,221
Summary of Number of Shares	The number of outstanding shares of the Company are as follows: 2021 2020 2019 2018 2017 Changes in share capital At January 1 53,750,386 47,985,837 42,135,448 36,984,292 32,421,121 Increase through cash contributions 3,187,296 5,764,549 5,850,389 5,151,156 4,563,171 At December 31 56,937,682 53,750,386 47,985,837 42,135,448 36,984,292
Summary Of Holding Of Treasury Shares	The holding of treasury shares are as follows: Nominal Holding Holding in (EUR’000) (Number) Treasury shares At January 1, 2021 — — — Acquired from third-parties 21 154,837 — At December 31, 2021 21 154,837 0.3%
Summary of Foreign Currency Sensitivity Analysis	Nominal Hypothetical impact on consolidated Increase in Profit and Equity (EUR ‘000) December 31, 2021 USD/EUR 549,243 10% 54,924 54,924 GBP/EUR 6,686 10% 669 669 December 31, 2020 USD/EUR 797,927 10% 79,793 79,793 GBP/EUR 1,555 10% 155 155
Summary Of Rate Structure Of Marketable Securities	Rate structure of marketable securities are specified below: December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by rate structure Fixed rate 323,176 322,556 175,757 175,732 Floating rate 17,975 17,968 16,975 16,972 Zero-coupon 2,207 2,207 56,826 56,826 Total marketable securities 249,558 249,530
Schedule Of Marketable Securities Specified BY Investment Grade Credit Rating	Marketable securities specified by investment grade credit rating are specified below: December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by investment grade credit rating Prime — — 7,716 7,714 High grade 144,307 144,030 142,339 142,352 Upper medium grade 196,909 196,566 99,503 99,464 Lower medium grade 2,142 2,135 — — Total marketable securities 343,358 342,731 249,558 249,530
Summary of Marketable securities	December 31, 2021 December 31, 2020 Carrying Fair value Carrying Fair value (EUR’000) Marketable securities specified by security type U.S. Treasury bills — — 46,243 46,245 U.S. Government bonds 95,408 95,211 62,088 62,101 Commercial papers 2,207 2,207 10,583 10,581 Corporate bonds 226,771 226,379 121,282 121,234 Agency bonds 18,972 18,934 9,362 9,369 Total marketable securities 343,358 342,731 249,558 249,530 Classified based on maturity profiles Non-current 107,561 107,175 115,280 115,277 Current assets 235,797 235,556 134,278 134,253 Total marketable securities 343,358 342,731 249,558 249,530
Summary of Maturity Analysis For Financial Liabilities	Maturity analysis for financial liabilities recognized in the consolidated statements of financial position are specified below. < 1 year 1-5 years >5 years Total Carrying (EUR’000) December 31, 2021 Lease liabilities 7,098 51,442 68,378 126,918 104,961 Trade payables and accrued expenses 59,417 — — 59,417 59,417 Total financial liabilities 66,515 51,442 68,378 186,335 164,378 < 1 year 1-5 years >5 years Total Carrying (EUR’000) December 31, 2020 Lease liabilities 6,974 38,321 68,516 113,811 91,975 Trade payables and accrued expenses 21,897 — — 21,897 21,897 Total financial liabilities 28,871 38,321 68,516 135,708 113,872

Investments in Group Enterpri_2

Investments in Group Enterprises (Tables)	12 Months Ended
	Dec. 31, 2021
Investments accounted for using equity method [abstract]
Summary of Investments in Group Enterprises	Ascendis Pharma A/S’s (parent company) investments in group enterprises at December 31, 2021, comprise: Subsidiaries Domicile Ownership Ascendis Pharma GmbH Germany 100% Ascendis Pharma, Inc. USA 100% Ascendis Pharma Endocrinology, Inc. USA 100% Ascendis Pharma Ophthalmology Division A/S Denmark 100% Ascendis Pharma Endocrinology Division A/S Denmark 100% Ascendis Pharma Bone Diseases A/S Denmark 100% Ascendis Pharma Growth Disorders A/S Denmark 100% Ascendis Pharma Oncology Division A/S Denmark 100% Associate Domicile Ownership VISEN Pharmaceuticals Cayman Island 43.93%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - Dec. 31, 2021	kr / shares	€ / shares
Disclosure of summary of significant accounting policies [line items]
Nominal value common shares | kr / shares	kr 1
Ordinary shares [member]
Disclosure of summary of significant accounting policies [line items]
Nominal value common shares | € / shares		€ 0.13

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Asset's Expected Useful Life (Detail)	12 Months Ended
	Dec. 31, 2021
Bottom of range [member] | Process plant and machinery [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	5 years
Bottom of range [member] | Other equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	3 years
Bottom of range [member] | Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	3 years
Bottom of range [member] | Right-of-use assets [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	2 years
Top of range [member] | Process plant and machinery [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	10 years
Top of range [member] | Other equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	5 years
Top of range [member] | Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	11 years
Top of range [member] | Right-of-use assets [member]
Disclosure of detailed information about property, plant and equipment [line items]
Asset's expected useful life	11 years

Significant Accounting Judgem_2

Significant Accounting Judgements and Estimates - Additional Information (Detail) € in Millions	12 Months Ended
	Dec. 31, 2021EUR (€)Licenses	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)
Disclosure of changes in accounting estimates [line items]
Project Cost Prepayments, Current	€ 8	€ 10.5
Project Cost Accruals, Current	23.5	17
Warrant compensation cost	€ 66.1	€ 53.2	€ 37.5
Bottom of range [member]
Disclosure of changes in accounting estimates [line items]
Additional lease period in additon to Non cancellable period	2 years
Top of range [member]
Disclosure of changes in accounting estimates [line items]
Additional lease period in additon to Non cancellable period	5 years
Right to use [member]
Disclosure of changes in accounting estimates [line items]
Number of licenses classified as right to use | Licenses	3

Revenue - Additional Informatio

Revenue - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Disclosure of associates [line items]
Percentage of ownership in the customer company	50.00%
Visen Pharmaceuticals [Member]
Disclosure of associates [line items]
Upfront payment received non cash consideration towards license revenue	$ 40
Percentage of ownership in the customer company	43.93%

Revenue - Schedule of Revenue R

Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from external customers
Commercial sale of products	€ 943
Rendering of services	751	€ 2,140	€ 9,919
Sale of clinical supply	3,719	2,206	804
"Right-to-use" licenses	2,365	2,607	2,652
Total revenue	7,778	6,953	13,375
Revenue from external customers (geographical)
Total revenue	7,778	6,953	13,375
Goods or services transferred over time [member]
Revenue from external customers
Total revenue	751	2,140	9,919
Revenue from external customers (geographical)
Total revenue	751	2,140	9,919
Goods or services transferred at point in time [member]
Revenue from external customers
Total revenue	7,027	4,813	3,456
Revenue from external customers (geographical)
Total revenue	7,027	4,813	3,456
Commercial customers [Member]
Revenue from external customers
Total revenue	943
Revenue from external customers (geographical)
Total revenue	943
Collaboration partners and license agreements [Member]
Revenue from external customers
Total revenue	6,835	6,953	13,375
Revenue from external customers (geographical)
Total revenue	6,835	6,953	13,375
North America [member]
Revenue from external customers
Total revenue	6,856	2,679	2,652
Revenue from external customers (geographical)
Total revenue	6,856	2,679	2,652
China [member]
Revenue from external customers
Total revenue	922	4,274	10,723
Revenue from external customers (geographical)
Total revenue	€ 922	€ 4,274	€ 10,723

Revenue - Schedule of Revenue_2

Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of operating segments [line items]
Deferred revenue from associate	€ 2.4	€ 3.5	€ 6.5
Collaboration partners and license agreements [Member]
Disclosure of operating segments [line items]
Percentage of entity's revenue	95.00%

Segment Information - Additiona

Segment Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021Segment
Disclosure of operating segments [line items]
Number of reportable segment	1

Segment Information - Summary o

Segment Information - Summary of Intangible Assets, and Property, Plant and Equipment (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement [LineItems]
Non-current segment assets	€ 131,321	€ 113,829
Investment in associate	38,345	9,176
Marketable securities	107,561	115,280
Other receivables	1,808	1,375
Total non-current assets	279,035	239,660
Denmark [member]
Statement [LineItems]
Non-current segment assets	29,656	20,288
North America [member]
Statement [LineItems]
Non-current segment assets	91,755	85,476
Germany [member]
Statement [LineItems]
Non-current segment assets	€ 9,910	€ 8,065

Employee Cost - Summary of Empl

Employee Cost - Summary of Employee Cost (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2021EUR (€)Employee	Dec. 31, 2020EUR (€)Employee	Dec. 31, 2019EUR (€)Employee
Disclosure of employee compensation costs [line items]
Wages and salaries	€ 104,583	€ 77,374	€ 49,142
Share-based payment	66,830	53,170	37,486
Pensions (defined contribution plans)	2,416	943	648
Social security costs	4,571	5,358	3,613
Key management personnel compensation	€ 178,400	€ 136,845	€ 90,889
Average number of employees | Employee	573	410	274
Research and development expenses [member]
Disclosure of employee compensation costs [line items]
Key management personnel compensation	€ 106,558	€ 92,468	€ 61,890
General and administrative expense [member]
Disclosure of employee compensation costs [line items]
Key management personnel compensation	70,462	44,377	28,999
Cost of sales [member]
Disclosure of employee compensation costs [line items]
Key management personnel compensation	1,380
Board of Directors [member]
Disclosure of employee compensation costs [line items]
Wages and salaries	296	250	265
Share-based payment	2,032	1,913	1,864
Key management personnel compensation	2,328	2,163	2,129
Executive Board [member]
Disclosure of employee compensation costs [line items]
Wages and salaries	2,699	2,372	1,815
Share-based payment	8,770	6,359	5,303
Pensions (defined contribution plans)	23
Social security costs	49	100	94
Key management personnel compensation	11,541	8,831	7,212
Nonexecutivesenior management [Member]
Disclosure of employee compensation costs [line items]
Wages and salaries	5,547	5,272	4,706
Share-based payment	14,906	13,912	11,123
Pensions (defined contribution plans)	120	89	54
Social security costs	60	122	84
Key management personnel compensation	€ 20,633	€ 19,395	€ 15,967

Employee Cost - Additional Info

Employee Cost - Additional Information (Detail) - Employee	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Board of Directors [member]
Disclosure of employee compensation costs [line items]
Number of persons		7	7
Board of Directors [member] | Maximum [Member]
Disclosure of employee compensation costs [line items]
Number of persons	7
Board of Directors [member] | Minimum [Member]
Disclosure of employee compensation costs [line items]
Number of persons	6
Executive Board [member]
Disclosure of employee compensation costs [line items]
Number of persons		2	2
Executive Board [member] | Maximum [Member]
Disclosure of employee compensation costs [line items]
Number of persons	4
Executive Board [member] | Minimum [Member]
Disclosure of employee compensation costs [line items]
Number of persons	2

Employee Cost - Warrant Activit

Employee Cost - Warrant Activity - Additional Information (Detail) - Warrants [member]	Dec. 31, 2021€ / shares
Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	€ 6.48
Top of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	€ 145.50

Share-based Payment - Schedule

Share-based Payment - Schedule of Warrant Activity (Detail)	12 Months Ended
	Dec. 31, 2021€ / shares	Dec. 31, 2020€ / shares	Dec. 31, 2019€ / shares
Disclosure Of Warrant Activity [line items]
Ending balance	7,085,073
Ending balance	€ 80.30
Warrants [member]
Disclosure Of Warrant Activity [line items]
Beginning balance	6,148,004	5,820,211	5,611,629
Granted during the year	1,445,981	1,485,931	1,300,600
Exercised during the year	(312,296)	(905,395)	(1,058,722)
Forfeited during the year	(196,616)	(252,743)	(33,296)
Expired during the year	0	0	0
Ending balance	7,085,073	6,148,004	5,820,211
Vested at the reporting date	4,022,011	3,044,827	2,705,693
Beginning balance	€ 69.97	€ 46.36	€ 29.03
Granted during the year	122.03	137.57	97.01
Exercised during the year	38.43	30.56	16.33
Forfeited during the year	119.58	64.99	58.49
Expired during the year	0	0	0
Ending balance	80.30	69.97	46.36
Vested at the reporting date	€ 52.63	€ 37.29	€ 24.93

Share-based Payment - Schedule

Share-based Payment - Schedule of Warrant Activity (Parenthetical) (Detail) - € / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
U.S. dollars [member]
Disclosure Of Warrant Activity [line items]
Weighted average share price	€ 124.62	€ 128.32	€ 108.54

Share-based Payment - Schedul_2

Share-based Payment - Schedule of Weighted Average Exercise Price and Weighted Remaining Contractual Life for Outstanding Warrants (Detail)	12 Months Ended
	Dec. 31, 2021€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of Warrants, Outstanding	7,085,073
Weighted Average Exercise, Outstanding	€ 80.30
Weighted Average Life, Granted	87 months
Granted In 2012-2017 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Year of grant	2012-2017
Number of Warrants, Granted	2,059,718
Weighted Average Exercise, Granted	€ 20.96
Weighted Average Life, Granted	53 months
Granted in 2018 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Year of grant	2018
Number of Warrants, Granted	1,209,072
Weighted Average Exercise, Granted	€ 54.52
Weighted Average Life, Granted	82 months
Granted In 2019 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Year of grant	2019
Number of Warrants, Granted	1,071,441
Weighted Average Exercise, Granted	€ 97.23
Weighted Average Life, Granted	93 months
Granted In 2020 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Year of grant	2020
Number of Warrants, Granted	1,310,094
Weighted Average Exercise, Granted	€ 137.89
Weighted Average Life, Granted	104 months
Granted In 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Year of grant	2021
Number of Warrants, Granted	1,434,748
Weighted Average Exercise, Granted	€ 122.03
Weighted Average Life, Granted	118 months

Share-based Payment - Summary

Share-based Payment - Summary of Fair Values for Warrant Grants (Detail) - Warrants [member]	12 Months Ended
	Dec. 31, 2021yr€ / shares	Dec. 31, 2020yr€ / shares	Dec. 31, 2019yr€ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected life of warrants (years) | yr	6
Weighted average exercise price | € / shares	€ 122.03	€ 137.57	€ 97.01
Bottom of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	48.00%	52.00%	52.00%
Risk-free interest rate	(0.54%)	(0.93%)	(0.77%)
Expected life of warrants (years) | yr		5.05	5.05
Fair value of warrants granted in the year | € / shares	€ 45.91	€ 48.43	€ 27.24
Top of range [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Expected volatility	49.00%	55.00%	54.00%
Risk-free interest rate	(0.27%)	(0.32%)	(0.05%)
Expected life of warrants (years) | yr		7.10	7.10
Fair value of warrants granted in the year | € / shares	€ 64.28	€ 75.77	€ 55.64

Share-Based Payment - Summary O

Share-Based Payment - Summary Of Share Based Payment (Detail)	12 Months Ended
	Dec. 31, 2021€ / shares
Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]
Ending balance	7,085,073
Ending balance	€ 80.30
Restricted Stock Units [Member]
Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]
Beginning balance	0
Granted	148,148
Ending balance	148,148
Vested at the reporting date	0
Beginning balance	€ 0
Granted	123.46
Ending balance	123.46
Vested at the reporting date	€ 0

Share-Based Payment - Additiona

Share-Based Payment - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021shares
Warrants Granted 2012 Until November 2021 [member]
Statement [LineItems]
Vesting period	24 months
Warrants Granted From December 2021 [member]
Statement [LineItems]
Vesting period	12 months
Board members of group [member]
Statement [LineItems]
Number of additional shares granted	1,316,588
Board members of group [member] | Warrants Granted From December 2021 [member]
Statement [LineItems]
Percentage of warrants vested	75.00%
Employees and consultants [member] | Warrants Granted From December 2021 [member]
Statement [LineItems]
Percentage of warrants vested	75.00%
Later than one year [member] | Warrants Granted 2012 Until November 2021 [member]
Statement [LineItems]
Vesting period	48 months
Later than one year [member] | Warrants Granted From December 2021 [member]
Statement [LineItems]
Vesting period	36 months
Later than one year [member] | Board members of group [member] | Warrants Granted From December 2021 [member]
Statement [LineItems]
Percentage of warrants vested	25.00%
Later than one year [member] | Employees and consultants [member] | Warrants Granted From December 2021 [member]
Statement [LineItems]
Percentage of warrants vested	25.00%

Principal Accountant Fees and_3

Principal Accountant Fees and Services - Summary of Principal Accountant Fees and Services (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Auditor's remuneration [abstract]
Audit fees	€ 771	€ 599	€ 700
Tax fees	87	104	7
All other fees	13	22
Total principal accountant fees and services	€ 871	€ 725	€ 707

Tax on Profit_(Loss) for the _3

Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax on profit/(loss) for the year:
Current tax (expense)/income	€ 367	€ 219	€ 234
Current tax expense (income) and adjustments for current tax of prior periods	367	219	234
Tax for the year can be explained as follows:
Profit/(loss) before tax	(383,944)	(419,174)	(218,250)
Tax at the Danish corporation tax rate of 22%	84,468	92,218	48,015
Tax effect of:
Non-deductible costs	(14,800)	(11,815)	(8,249)
Additional tax deductions	17,117	24,564	10,875
Impact from associate	3,169	(1,326)	(1,680)
Other effects including effect of different tax rates	305	2,673	1,602
Deferred tax asset, not recognized	(89,892)	(106,095)	(50,329)
Tax on profit/(loss) for the year	€ 367	€ 219	€ 234
Effective tax rate	(0.10%)	(0.05%)	(0.11%)
Tax deductible losses	€ 313,011	€ 227,234	€ 123,234
Other temporary differences	12,856	7,726	5,631
Deferred tax asset, not recognized	(325,867)	(234,960)	(128,865)
Total Deferred Tax Assets at December 31	€ 0	€ 0	€ 0

Tax on Profit_(Loss) for the _4

Tax on Profit/(Loss) for the Year and Deferred Tax - Summary of Tax on Profit/Loss and Deferred Tax (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major components of tax expense (income) [abstract]
Applicable tax rate	22.00%	22.00%	22.00%

Tax on Profit_(Loss) for the _5

Tax on Profit/(Loss) for the Year and Deferred Tax - Additional Information (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major components of tax expense (income) [abstract]
Income taxes refund	€ 0.7	€ 0.7	€ 0.7
Tax losses carryforwards	1,437	1,043.8
Additional tax deductions, determined by annual warrants exercises by employees	€ 4.8	€ 16.3	€ 10.2

Intangible Assets - Summary of

Intangible Assets - Summary of Goodwill (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	€ 5,717
Intangible assets at ending period	5,272	€ 5,717
Goodwill [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	3,495
Intangible assets at ending period	3,495	3,495
Computer software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	2,222
Intangible assets at ending period	1,777	2,222
Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	5,717	3,495
Additions		2,222
Disposals
Foreign exchange translation
Intangible assets at ending period	5,717	5,717
Gross carrying amount [member] | Goodwill [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	3,495	3,495
Additions
Disposals
Foreign exchange translation
Intangible assets at ending period	3,495	3,495
Gross carrying amount [member] | Computer software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period	2,222
Additions		2,222
Disposals
Foreign exchange translation
Intangible assets at ending period	2,222	2,222
Accumulated impairment [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period
Amortization Charge	(445)
Impairment charge
Disposals
Foreign exchange translation
Intangible assets at ending period	(445)
Accumulated impairment [member] | Goodwill [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period
Amortization Charge
Impairment charge
Disposals
Foreign exchange translation
Intangible assets at ending period	0
Accumulated impairment [member] | Computer software [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets at beginning period
Amortization Charge	(445)
Impairment charge
Disposals
Foreign exchange translation
Intangible assets at ending period	€ (445)

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	€ 108,112
Depreciation charge	(14,946)	€ (9,448)	€ (6,688)
Property, plant and equipment at ending period	126,049	108,112
Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	127,898	56,389
Additions	25,788	78,235
Disposals	(1,822)	(531)
Foreign exchange translation	8,106	(6,195)
Property, plant and equipment at ending period	159,970	127,898	56,389
Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	(19,786)		(11,320)
Depreciation charge	(14,946)		(9,448)
Disposals	1,822		402
Foreign exchange translation	(1,011)		580
Property, plant and equipment at ending period	(33,921)	(19,786)
Plant and machinery [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	9,841
Property, plant and equipment at ending period	11,419	9,841
Plant and machinery [member] | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	14,622	8,038
Additions	2,810	7,169
Disposals	(772)	(296)
Foreign exchange translation	286	(289)
Property, plant and equipment at ending period	16,946	14,622	8,038
Plant and machinery [member] | Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	(4,781)		(3,971)
Depreciation charge	(1,499)		(1,030)
Disposals	772		204
Foreign exchange translation	(19)		16
Property, plant and equipment at ending period	(5,527)	(4,781)
Other equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	2,888
Property, plant and equipment at ending period	5,275	2,888
Other equipment [member] | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	5,175	3,944
Additions	3,386	1,635
Disposals	(10)	(221)
Foreign exchange translation	271	(183)
Property, plant and equipment at ending period	8,822	5,175	3,944
Other equipment [member] | Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	(2,287)		(1,563)
Depreciation charge	(1,200)		(956)
Disposals	10		191
Foreign exchange translation	(70)		41
Property, plant and equipment at ending period	3,547	(2,287)
Leasehold improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	7,401
Property, plant and equipment at ending period	15,579	7,401
Leasehold improvements [member] | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	8,535	4,288
Additions	8,780	4,849
Disposals		(14)
Foreign exchange translation	752	(588)
Property, plant and equipment at ending period	18,067	8,535	4,288
Leasehold improvements [member] | Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	(1,134)		(558)
Depreciation charge	(1,284)		(605)
Disposals			7
Foreign exchange translation	(70)		22
Property, plant and equipment at ending period	(2,488)	(1,134)
Right-of-use assets [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	87,982
Property, plant and equipment at ending period	93,776	87,982
Right-of-use assets [member] | Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	99,566	40,119
Additions	10,812	64,582
Disposals	(1,040)
Foreign exchange translation	6,797	(5,135)
Property, plant and equipment at ending period	116,135	99,566	40,119
Right-of-use assets [member] | Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment at beginning period	(11,584)		(5,228)
Depreciation charge	(10,963)		(6,857)
Disposals	1,040
Foreign exchange translation	(852)		€ 501
Property, plant and equipment at ending period	€ (22,359)	€ (11,584)

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - EUR (€)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Assets under construction amounts	€ 1,900	€ 2,300
Construction expenditure incurred but not paid	€ 2,100	€ 1,000

Property, Plant and Equipment_3

Property, Plant and Equipment - Summary of Depreciations Charges (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about depreciations charges [Line Items]
Depreciations charges	€ 14,946	€ 9,448	€ 6,688
Cost of sales [member]
Disclosure of detailed information about depreciations charges [Line Items]
Depreciations charges	252
Research and development costs [member]
Disclosure of detailed information about depreciations charges [Line Items]
Depreciations charges	10,102	7,311	5,282
Selling General And Administrative Expense [Member]
Disclosure of detailed information about depreciations charges [Line Items]
Depreciations charges	€ 4,592	€ 2,137	€ 1,406

Investment in Associate - Addit

Investment in Associate - Additional Information (Detail) € in Thousands, $ in Millions	Jan. 08, 2021EUR (€)	Jan. 08, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2021USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019EUR (€)
Disclosure of associates [line items]
Ownership			50.00%	50.00%
Share of profit/(loss) of associate | €			€ 12,041		€ (9,524)	€ (8,113)
Major business combination [member]
Disclosure of associates [line items]
Consideration received		$ 150
VISEN
Disclosure of associates [line items]
Ownership			43.93%	43.93%	50.00%
Consideration received				$ 40
Share of profit/(loss) of associate | €	€ 42,300
Proportion of voting rights held in associate			43.93%	43.93%
VISEN | Major business combination [member]
Disclosure of associates [line items]
Consideration received		$ 12.5

Investment in Associate - Sched

Investment in Associate - Schedule of Financial Information of Investment in VISEN (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
VISEN Pharmaceuticals
Ownership	50.00%
Statement of Profit or loss
Total comprehensive income/(loss)	€ (379,722)	€ (418,997)	€ (218,053)
Statement of financial position
Non-current assets	279,035	239,660
Current assets	805,886	740,133
Total assets	1,084,921	979,793
Equity	883,635	838,711	€ 597,114	€ 280,050
Non-current liabilities	100,930	88,278
Current liabilities	100,356	52,804
Total equity and liabilities	€ 1,084,921	€ 979,793
VISEN Pharmaceuticals [member]
VISEN Pharmaceuticals
Principal place of business	China
Ownership	43.93%	50.00%
Statement of Profit or loss
Profit / (loss) for the year from continuing operations	€ (69,283)	€ (19,049)
Total comprehensive income/(loss)	69,306	(19,049)
Statement of financial position
Non-current assets	16,599	16,635
Current assets	130,825	20,373
Total assets	147,424	37,008
Equity	135,333	33,708
Non-current liabilities	1,545	152
Current liabilities	10,546	3,148
Total equity and liabilities	147,424	37,008
Transactions and outstanding balances as of December 31
Sale of goods and services to associate	6,472	6,880
Trade receivables	1,644	184
Contract liabilities	€ 5,565	€ 0

Investment in Associate - Equit

Investment in Associate - Equity (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of associates and joint ventures [line items]
Investment in associate	€ 38,345	€ 9,176
VISEN Pharmaceuticals [member] | Associates [member]
Disclosure of associates and joint ventures [line items]
Company's share of equity before eliminations	59,455	16,854
Elimination of internal profit recognized	(21,110)	(7,678)
Company's share of equity after eliminations	38,345	9,176
Investment in associate	€ 38,345	€ 9,176

Inventories - Summary of Invent

Inventories - Summary of Inventories Explanatory (Detail) € in Thousands	Dec. 31, 2021EUR (€)
Summary of Inventory Disclosure [Line Items]
Raw materials and consumables	€ 2,248
Work in progress	68,865
Finished goods	4,292
Total inventories	€ 75,405

Inventories - Additional Inform

Inventories - Additional Information (Detail) € in Millions	12 Months Ended
	Dec. 31, 2021EUR (€)
Text block [abstract]
Reversal of inventory write-down	€ 53.7

Leases - Additional Information

Leases - Additional Information (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Lease Term	2 years
Lease liabilities	€ 104,961	€ 91,975	€ 36,619
Denmark [member] | Additional Office Facility [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Enforceable LeaseTerm	4 years
Lease Commence Period	January 2022
Lease liabilities	€ 2,300
Bottom of range [member]
Disclosure of maturity analysis of operating lease payments [line items]
Optional Lease Extension Period	2 years
Top of range [member]
Disclosure of maturity analysis of operating lease payments [line items]
Optional Lease Extension Period	5 years
Lease Term	11 years

Leases - Summary of Development

Leases - Summary of Development In Lease Liabilities (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Text block [abstract]
Beginning of period	€ 91,975	€ 36,619
Payment of principal portion of liabilities	(6,429)	(4,781)
Payment of interest	(1,326)	(1,209)
Additions	10,812	64,582
Accretion of interest	3,396	1,617	€ 1,014
Foreign exchange adjustment	6,533	(4,853)
End of period	€ 104,961	€ 91,975	€ 36,619

Leases - Summary of Expenses, R

Leases - Summary of Expenses, Relating To Lease Activities In The Consolidated Statements (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation	€ 10,963	€ 6,857	€ 5,237
Expenses relating to short term leases and leases of low value assets	186	470	202
Lease interest	3,396	1,617	1,014
Total lease expenses	€ 14,545	€ 8,944	€ 6,453

Contract Liabilities - Addition

Contract Liabilities - Additional Information (Detail) - EUR (€) € in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Contract Liabilities [Line Items]
Revenue recognized from contract liabilities	€ 0.4	€ 1	€ 6.1
Two Thousand And Twenty Two [Member]
Contract Liabilities [Line Items]
Contract liabilities are expected to be recognized as revenue	2.6
Two Thousand And Twenty Three To Two Thousand And Twenty Six [Member]
Contract Liabilities [Line Items]
Contract liabilities are expected to be recognized as revenue	€ 3

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - EUR (€) € in Millions	Dec. 31, 2021	Dec. 31, 2020
Leasehold improvements [member]
Disclosure of commitments and contingencies [line items]
Contractual commitments	€ 8.4	€ 15.8

Financial Risk Management and_3

Financial Risk Management and Financial Instruments - Schedule of Financial assets and Liabilities (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Financial assets:
Cash and cash equivalents	€ 446,267	€ 584,517	€ 598,106	€ 277,862
Financial liabilities
Lease liabilities	104,961	91,975	€ 36,619
Financial liabilities at amortised cost, class [member]
Financial liabilities
Lease liabilities	104,961	91,975
Trade payables	59,417	21,897
Financial liabilities measured at amortized cost	164,378	113,872
Financial assets at amortised cost, class [member]
Financial assets:
Trade receivables	2,200	387
Other receivables	12,276	2,251
Marketable Securities	343,358	249,558
Cash and cash equivalents	446,267	584,517
Financial assets measured at amortized cost	€ 804,101	€ 836,713

Financial Risk Management and_4

Financial Risk Management and Financial Instruments - Schedule of Finance Income and Finance Expenses (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance income
Interest income	€ 692	€ 1,812	€ 10,056
Exchange rate gains	59,026		7,747
Total finance income	59,718	1,812	17,803
Finance expenses
Interest expenses	3,911	1,918	1,221
Exchange rate losses		78,924
Total finance expenses	€ 3,911	€ 80,842	€ 1,221

Financial Risk Management and_5

Financial Risk Management and Financial Instruments - Summary of Number of Shares (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Share capital beginning of year	53,750,386	47,985,837	42,135,448	36,984,292	32,421,121
Increase through cash contribution	3,187,296	5,764,549	5,850,389	5,151,156	4,563,171
Share capital end of year	56,937,682	53,750,386	47,985,837	42,135,448	36,984,292

Financial Risk Management and_6

Financial Risk Management and Financial Instruments - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Sep. 29, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Number of shares issued	56,937,682		53,750,386	47,985,837	42,135,448	36,984,292	32,421,121
American Depositary Shares [Member]
Disclosure of detailed information about financial instruments [line items]
Share repurchase program, Number of shares authorized to be repurchased		25
Liquidity risk [member]
Disclosure of detailed information about financial instruments [line items]
Weighted Average Duration Of Marketable Securities Current	5 months 24 days
Weighted Average Duration Of Marketable Securities Noncurrent	16 months 21 days
Weighted Average Duration Of Marketable Securities	9 months 6 days
Financial Assets Duration Period	12 months
Danish Kroner (DKK) [member]
Disclosure of detailed information about financial instruments [line items]
Foreign currency target percentage	4.50%

Financial Risk Management and_7

Financial Risk Management and Financial Instruments - Summary of Holding of Treasury Shares (Detail) € in Thousands	12 Months Ended
	Dec. 31, 2021EUR (€)shares
Disclosure Of Holding Of Treasury Shares [Line Items]
At January 1, 2021 (Nominal value) | €	€ 0
Acquired from third-parties (Nominal value) | €	21
At December 31, 2021 (Nominal Value) | €	€ 21
At January 1, 2021 (Holding) | shares	0
Acquired from third-parties (Holding) | shares	154,837
At December 31, 2021 (Holding) | shares	154,837
At January 1, 2021 (Holding in % of total outstanding shares)	0.00%
Acquired from third-parties (Holding in 1% total outstanding shares)	0.00%
At December 31, 2021 (Holding in % of total outstanding shares)	0.30%

Financial Risk Management and_8

Financial Risk Management and Financial Instruments - Schedule of Foreign Currency Sensitivity Analysis (Detail) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
US dollars to Euro [member]
Disclosure of detailed information about financial instruments [line items]
Nominal positions	€ 549,243	€ 797,927
Increase in foreign exchange rate	10.00%	10.00%
Profit and loss before tax	€ 54,924	€ 79,793
Equity before tax	54,924	79,793
British pounds to Euro [member]
Disclosure of detailed information about financial instruments [line items]
Nominal positions	€ 6,686	€ 1,555
Increase in foreign exchange rate	10.00%	10.00%
Profit and loss before tax	€ 669	€ 155
Equity before tax	€ 669	€ 155

Financial Risk Management and_9

Financial Risk Management and Financial Instruments - Schedule of Marketable Securities Specified BY Investment Grade Credit Rating (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial marketable securities	€ 343,358	€ 249,558
Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial marketable securities	342,731	249,530
Credit risk [member] | Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial marketable securities	343,358	249,558
Credit risk [member] | Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial marketable securities	342,731	249,530
Credit risk [member] | Prime [Member] | Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	0	7,716
Credit risk [member] | Prime [Member] | Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	0	7,714
Credit risk [member] | High Grade [Member] | Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	144,307	142,339
Credit risk [member] | High Grade [Member] | Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	144,030	142,352
Credit risk [member] | Upper Medium Grade [Member] | Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	196,909	99,503
Credit risk [member] | Upper Medium Grade [Member] | Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	196,566	99,464
Credit risk [member] | Lower Medium Grade [Member] | Financial assets at amortised cost, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	2,142	0
Credit risk [member] | Lower Medium Grade [Member] | Financial assets at fair value, class [member]
Disclosure Of Marketable Securities Specified By Investment Grade Credit Rating [Line Items]
Financial assets	€ 2,135	€ 0

Financial Risk Management an_10

Financial Risk Management and Financial Instruments - Summary of Marketable securities (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Detailed Information About Marketable Securities [Line Items]
Non-current financial marketable securities	€ 107,561	€ 115,280
Current financial marketable securities	235,797	134,278
Financial assets at amortised cost, class [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	343,358	249,558
Financial assets at amortised cost, class [member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	343,358	249,558
Non-current financial marketable securities	107,561	115,280
Current financial marketable securities	235,797	134,278
Financial assets at amortised cost, class [member] | US Treasury bills [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities		46,243
Financial assets at amortised cost, class [member] | US Government Bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	95,408	62,088
Financial assets at amortised cost, class [member] | Commercial papers [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	2,207	10,583
Financial assets at amortised cost, class [member] | Corporate bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	226,771	121,282
Financial assets at amortised cost, class [member] | Agency bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	18,972	9,362
Financial assets at fair value, class [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	342,731	249,530
Financial assets at fair value, class [member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	342,731	249,530
Non-current financial marketable securities	107,175	115,277
Current financial marketable securities	235,556	134,253
Financial assets at fair value, class [member] | US Treasury bills [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities		46,245
Financial assets at fair value, class [member] | US Government Bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	95,211	62,101
Financial assets at fair value, class [member] | Commercial papers [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	2,207	10,581
Financial assets at fair value, class [member] | Corporate bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	226,379	121,234
Financial assets at fair value, class [member] | Agency bonds [Member] | Liquidity risk [member]
Disclosure Detailed Information About Marketable Securities [Line Items]
Financial marketable securities	€ 18,934	€ 9,369

Financial Risk Management an_11

Financial Risk Management and Financial Instruments - Liquidity Risk Management (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis for derivative financial liabilities [line items]
Lease liabilities	€ 104,961	€ 91,975	€ 36,619
Trade payables	59,417	21,897
Total financial liabilities	164,378	113,872
Lease liabilities	126,918	113,811
Trade payables	59,417	21,897
Total financial liabilities	186,335	135,708
Within 1 year [member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Lease liabilities	7,098	6,974
Trade payables	59,417	21,897
Total financial liabilities	66,515	28,871
Within 1 to 5 years [member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Lease liabilities	51,442	38,321
Trade payables	0	0
Total financial liabilities	51,442	38,321
After 5 years [member]
Disclosure of maturity analysis for derivative financial liabilities [line items]
Lease liabilities	68,378	68,516
Trade payables	0	0
Total financial liabilities	€ 68,378	€ 68,516

Financial Risk Management an_12

Financial Risk Management and Financial Instruments - Summary of Rate Structure of Marketable Securities (Detail) - EUR (€) € in Thousands	Dec. 31, 2021	Dec. 31, 2020
Financial assets at amortised cost, class [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial marketable securities	€ 343,358	€ 249,558
Financial assets at amortised cost, class [member] | Floating interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	17,975	16,975
Financial assets at amortised cost, class [member] | Fixed interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	323,176	175,757
Financial assets at amortised cost, class [member] | Zero Coupon [Member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	2,207	56,826
Financial assets at fair value, class [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial marketable securities	342,731	249,530
Financial assets at fair value, class [member] | Floating interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	17,968	16,972
Financial assets at fair value, class [member] | Fixed interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	322,556	175,732
Financial assets at fair value, class [member] | Zero Coupon [Member]
Disclosure of financial instruments by type of interest rate [line items]
Financial assets	€ 2,207	€ 56,826

Investments in Group Enterpri_3

Investments in Group Enterprises - Summary of Investments in Group Enterprises (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Ownership	50.00%
Ascendis Pharma GmbH [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma GmbH
Domicile	Germany
Ownership	100.00%
Ascendis Pharma, Inc [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma, Inc.
Domicile	USA
Ownership	100.00%
Ascendis Pharma Endocrinology, Inc. [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Endocrinology, Inc.
Domicile	USA
Ownership	100.00%
Ascendis Pharma Ophthalmology Division A/S [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Ophthalmology Division A/S
Domicile	Denmark
Ownership	100.00%
Ascendis Pharma Endocrinology Division A/S [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Endocrinology Division A/S
Domicile	Denmark
Ownership	100.00%
Ascendis Pharma Bone Diseases A/S [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Bone Diseases A/S
Domicile	Denmark
Ownership	100.00%
Ascendis Pharma Growth Disorders A/S [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Growth Disorders A/S
Domicile	Denmark
Ownership	100.00%
Ascendis Pharma Oncology Division AS [member]
Disclosure of subsidiaries [line items]
Company	Ascendis Pharma Oncology Division A/S
Domicile	Denmark
Ownership	100.00%
Visen Pharmaceuticals [member]
Disclosure of subsidiaries [line items]
Company	VISEN Pharmaceuticals
Domicile	Cayman Island
Ownership	43.93%	50.00%

Ownership - Additional Informat

Ownership - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership percentage	5.00%
T Rowe Price Associates Inc [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	T. Rowe Price Associates, Inc., USA
Entities affiliated with RA capital management LLC [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Entities affiliated with RA Capital Management, LLC, USA
Entities affiliated with Artisan Partners Limited Partnership [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Entities affiliated with Artisan Partners Limited Partnership, USA
Entities affiliated with FMR LLC [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Entities affiliated with FMR LLC, USA
Baker Bros. advisors LP [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Baker Bros. Advisors LP, USA
Entities affiliated with Wellington Management Group LLP [Member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Entities affiliated with Wellington Management Group LLP, USA
Entities affiliated with Janus Henderson Group plc [member] | USA [member]
Disclosure of beneficial ownership [line items]
Minimum beneficial ownership	Entities affiliated with Janus Henderson Group plc, United Kingdom

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - EUR (€)	Feb. 20, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of non-adjusting events after reporting period [line items]
Lease liabilities		€ 104,961,000	€ 91,975,000	€ 36,619,000
Events After Reporting Period [Member] | DENMARK | Office Facility [Member]
Disclosure of non-adjusting events after reporting period [line items]
Enforceable LeaseTerm	15 years
Expected Lease Commence Year	2025
Lease liabilities	€ 55,200
Right-of-use assets	€ 55,200